

HUMIC ACID

**PROCESS FOR PREPARING SYNTHETIC SOIL-
EXTRACT MATERIALS AND MEDICAMENTS
BASED THEREON**

***World Intellectual Property
Organization***



***Laub BioChemicals Corporation
1401 Quail St., Suite 121
Newport Beach, CA 92660***

August 1998

13 August/aout 1998

32/1998

PCT GAZETTE DU PCT

**International Applications
Under the Patent Cooperation Treaty (PCT)
Demandes internationales en vertu du
Traité de coopération en matière de brevets (PCT)**

**International Publication Numbers
Numéros de publication internationale
WO 98/34455—WO 98/35543**



World Intellectual Property Organization

World Intellectual Property Organization (WIPO) — Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) — Genève, Suisse

© WIPO/OMPI

ISSN 0250-7757

<i>CONTENTS</i>	Page	<i>SOMMAIRE</i>
Section I Published International Applications	12195	Section 1 Demandes internationales publiées
Section II Notices and Information Relating to Published International Applications and/or Entries in Section I		Section II Notifications et informations relatives aux demandes internationales publiées et/ou aux rubriques de la Section 1
Announcement of the Later Publication of Amended Claims (and, Where Applicable, Statement Under Article 19)	12363	Annonce de la publication ultérieure des revendications modifiées (et, s' il y a lieu, de la déclaration selon l' article 19)
Announcement of the Withdrawal of International Applications After International Publication	12364	Annonce du retrait de demandes internationales après publication internationale
Announcement of the Later Publication of International Search Reports	12368	Annonce de la publication ultérieure de rapports de recherche internationale
Corrections of Entries in Section I	12371	Corrections de rubriques de la Section I
Corrected Versions of Pamphlets		Versions corrigées de brochures
International Applications for Which a Demand Has Been Filed Prior to the Expiration of the 19th Month from the Priority Date	12378	Demandes internationales pour lesquelles une demande d'examen préliminaire international a été présentée avant l' expiration d' une période de 19 mois à compter de la date de priorité
Section III Weekly Indexes		Section III Index hebdomadaires
International Application Numbers and Corresponding International Publication Numbers	12391	Numéros des demandes internationales et numéros de publication internationale correspondants
Names of Applicants and Corresponding International Publication Numbers	12397	Noms des déposants et numéros de publication internationale correspondants
International Publication Numbers Grouped According to International Patent Classification Symbols	12413	Numéros de publication internationale répartis en fonction des symboles de la classification internationale des brevets
Section IV Notifications and Information of a General Character	12421	Section IV Notifications et informations de caractère général

GUIDANCE NOTES ON CODES AND ABBREVIATIONS

NOTES EXPLICATIVES RELATIVES AUX CODES ET ABBRÉVIATIONS

The entry for each published international application includes applicable items of bibliographic data as well as indications in certain cases about the contents of the published pamphlet of the applications. Where possible, codes are used for these purposes, as explained on the following pages.

L'entrée correspondant à chaque demande internationale publiée comprend les éléments de données bibliographiques applicables ainsi que, dans certains cas, des indications concernant le contenu de la brochure publiée de la demande. Chaque fois que possible, des codes sont utilisés pour cela, comme expliqué sur les pages qui suivent.

TWO-LETTER CODES
FOR PCT CONTRACTING STATES, REGIONAL PATENT OFFICES
AND THE INTERNATIONAL BUREAU

(Other two-letter codes appear in International Standard ISO 3166, in WIPC) Standard ST.3. published in
PCT Gazette No. 2011992, and in Annex K of the PCI' Applicant's Guide, Vol. I/B)

AL	Albania	IE	Ireland	SI	Slovenia
AM	Armenia	IL	Israel	SK	Slovakia
AT	Austria	IS	Iceland	SL	Sierra Leone
AU	Australia	IT	Italy	SN	Senegal
AZ	Azerbaijan	JP	Japan	SZ	Swaziland
BA	Bosnia and Heizegovina	KE	Kenya	TD	Chad
BB	Barbados	KG	Kyrgyzstan	TG	Togo
BE	Belgium	KP	Democratic People's	TJ	Tajikistan
BF	Burkina Faso		Republic of Korea	TM	Turkmenistan
BG	Bulgaria	KR	Republic of Korea	TR	Turkey
BJ	Benin	KZ	Kazakhstan	TT	Trinidad and Tobago
BR	Brazil	LC	Saint Lucia	UA	Ukraine
BY	Belams	LI	Liechtenstein	UG	Uganda
CA	Canada	LK	Sri Lanka	US	United States of America
CF	Central African Republic	LR	Uberia	UZ	Uzbekistan
CG	Congo	LS	Lesotho	VN	Viet Nam
CH	Switzerland	LT	Lithuania	YU	Yugoslavia
CI	C6te d'Ivoire	LU	Luxembourg	ZW	Zimbabwe
CM	Cameroon	LV	Latvia		
CN	China	MC	Monaco		
CU	Cuba	MD	Republic of Moldova	AP	Office of the African Regional Industrial Property Organization (ARIK))
CY	Cyprus	MG	Madagascar	FA	Eurasian Patent Office (FAPO)
CZ	Czech Republic	MK	The former Yugoslav Republic of Macedonia	EP	European Patent Office (EPO)
DE	Germany	ML	Mali	OA	African Intellectual Property Organization (OAPI)
DK	Denmark	MN	Mongolia		
FE	Estonia	MR	Mauritania		
ES	Spain	MW	Malawi		
FI	Finland	MX	Mexico		
FR	France	NE	Niger		
GA	Gabon	NL	Netherlands		
GB	United Kingdom	NO	Norway		
GE	Georgia	NZ	New Zealand		
GH	Ghana	PL	Poland	IB	International Bureau of the World Intellectual Property Organization (WIPO)
GM	Gambia	PT	Portugal		
GN	Guinea	RO	Romania		
GR	Greece	RU	Russian Federation	WO	World Intellectual Property Organization (WIPO) (International Bureau of)
GW	Guinea-Bissau	SD	Sudan		
I-JR	Croatia	SF	Sweden		
I-RJ	Hungary	SG	Singapore		
ID	Indonesia				

CODES À DEUX LETTRES
POUR L'IDENTIFICATION DES ÉTATS CONTRACTANTS DU PCT,
DES OFFICES DE BREVETS RÉGIONAUX ET DU BUREAU INTERNATIONAL

(D'autres codes à deux lettres figurent dans la norme internationale ISO 3166, dans la norme ST.3 de l'OMPI, publiée dans la Gazette du PCI' n° 20/1992, et dans l'annexe K du Guide du déposant du PCI', vol. I/B)

AL	Albanie	IF	Irlande	SI	Slovénie
AM	Arménie	IL	Israël	SK	Slovaquie
AT	Autriche	IS	Islande	SL	Sierra Leone
AU	Australie	IT	Italie	SN	Sénégal
AZ	Azerbaïdjan	JP	Japon	SZ	Swaziland
BA	Bosnie-Herzégovine	KE	Kenya	TD	Tchad
BB	Barbade	KG	Kirghizistan	TG	Togo
BE	Belgique	KP	République populaire démocratique de Corée	TJ	Tadjikistan
BF	Burkina Faso	KR	République de Corée	TM	Turkménistan
BG	Bulgarie	KZ	Kazakhstan	TR	Turquie
BJ	Bénin	LC	Sainte-Lucie	TT	Trinité-et-Tobago
BR	Brésil	LI	Liechtenstein	UA	Ukraine
BY	Bélarus	LK	Sri Lanka	UG	Ouganda
CA	Canada	LR	Libéria	US	États-Unis d'Amérique
CF	République centrafricaine	LS	Lesotho	UZ	Ouzbékistan
CG	Congo	LT	Lituanie	VN	Viet Nam
CH	Suisse	LU	Luxembourg	YU	Yougoslavie
CI	Côte d'Ivoire	LV	Lettonie	ZW	Zimbabwe
CM	Cameroun	MC	Monaco		
CN	Chine	MD	République de Moldova		
CU	Cuba	MG	Madagascar		
CY	Chypre	MR	Ex-République yougoslave de Macédoine	AP	Office de l'Organisation régionale africaine de la propriété industrielle (ARIFO)
CZ	République tchèque	ML	Mali	FA	Office eurasiatique des brevets (OFAB)
DE	Allemagne	MN	Mongolie	EP	Office européen des brevets (OEB)
DK	Danemark	MR	Mauritanie	OA	Organisation africaine de la propriété intellectuelle (OARI)
EE	Estonie	MW	Malawi	IB	Bureau international de l'Organisation Mondiale de la Propriété Intellectuelle (OMPI)
ES	Espagne	MX	Mexique	WO	Organisation Mondiale de la Propriété Intellectuelle (OMPI) (Bureau international de l')
FI	Finlande	NE	Niger		
FR	France	NL	Pays-Bas		
GA	Gabon	NO	Norvège		
GB	Royaume-Uni	NZ	Nouvelle-Zélande		
GE	Géorgie	PL	Pologne		
GH	Ghana	PT	Portugal		
GM	Gambie	RO	Roumanie		
GN	Guinée	RU	Fédération de Russie		
GR	Grèce	SD	Soudan		
GW	Guinée-Bissau	SF	Suède		
HR	Croatie	SG	Singapour		
HU	Hongrie				
ID	Indonésie				

INID CODES

(from WIPO Standard ST.9)

- (11) International publication number
- (13) Kind-of--document code according to WIPO Standard ST. 16
 - A1 Published with international search report
 - A2 Published without international search report and to be republished upon receipt of that report
 - A3 Subsequent publication of the international search report together with a revised version of the front page of the pamphlet
- (21) International application number
- (22) International filing date
- (25) Language in which the international application was originally filed
- (26) Language in which the international application is published
- (31) Priority number
- (32) Priority date
- (33) Office with which the priority application was filed
- (34) Countries for which the regional or international application was made
- (43) International publication date
- (51) International Patent Classification (superscript numeral indicates edition)
- (54) Title of the invention
- (61) Related by addition to earlier application or grant <country> <number> <date>
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application <country> <number> <date>
- (71) Applicant(s), including indications in square brackets of [State of nationality/State of residence]
- (72) Inventor(s)
- (74) Agent(s)/Common representative
- (75) Inventor(s)/Applicant(s) (for US only), including indications in square brackets of [State of nationality/State of residence]
- (81) Designated States

OTHER CODES

The codes below appearing after the heading "Published/Publi6e indicate that the corresponding text matter was published on the front page of the PCT pamphlet:

- (a) With amended claims.
 - (b) With amended claims and statement
 - (c) Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
 - (d) Upon request of the applicant under Article 64(3)(cXi).
 - (e) In accordance with Article 64(3)(c)(ii) upon publication of a patent based on the international application referred to herein, issued by the United States Patent and Trademark Office on <date> under serial number <numbei>.
 - (f) Before the expiration of the time limit referred to in Article 21(2Xa) on the request of the applicant
 - (g) Without classification; title and abstract not checked by the International Searching Authority.
 - (h) With declaration under Article 17(2)(a). Without classification and without abstract; title not checked by the International Searching Authority.
 - (i) With declaration under Article 17(2)(a). Without abstract; title not checked by the International Searching Authority.
 - (k) With a request for rectification under Rule 91.1
 - (m) With an indication in relation to a deposited microorganism furnished under Rule 13"" separately from the description.
- Date of receipt by the International Bureau: <date>.
- (n) With a statement concerning non-prejudicial disclosure or exception to lack of novelty.
 - (p) With an indication in relation to a priority claim considered not to have been made.

CODES FOR THE REPRESENTATION
OF NAMES OF LANGUAGES

(from International Standard ISO 639: 1988)

Code	Language	Code	Language
da	Danish	ja	Japanese
de	German	nl	Dutch
en	English	no	Norwegian
es	Spanish	ru	Russian
fi	Finnish	sv	Swedish
fr	French	zh	Chinese

CODES INID

AUTRES CODES

(de la norme ST.9 de l'OMPI)

- | | |
|---|--|
| <p>(11) Numéro de la publication internationale</p> <p>(13) Code du type de document selon la norme ST.16 de l'OMPI</p> <p style="padding-left: 20px;">A1 Publiée avec rapport de recherche internationale</p> <p style="padding-left: 20px;">A2 Publiée sans rapport de recherche internationale, sera republiée des réception de ce rapport</p> <p style="padding-left: 20px;">A3 Publication ultérieure du rapport de recherche internationale avec une version révisée de la page de couverture de la brochure</p> <p>(21) Numéro de la demande internationale</p> <p>(22) Date du dépôt international</p> <p>(25) Langue dans laquelle la demande internationale a initialement déposée</p> <p>(26) Langue dans laquelle la demande internationale est publiée</p> <p>(31) Numéro de priorité</p> <p>(32) Date de priorité</p> <p>(33) Office auprès duquel la demande de priorité a été déposée</p> <p>(34) Pays pour lesquels la demande régionale ou internationale a été déposée</p> <p>(43) Date de la publication internationale</p> <p>(51) Classification internationale des brevets (l'exposant en chiffre arabe indique l'édition)</p> <p>(54) Titre de l'invention</p> <p>(61) Apparenté(e) par addition à un brevet ou une demande antérieur(e) <pays> <numero> <date></p> <p>(63) Apparenté(e) par continuation (CON) ou par continuation partielle (CII') <i>ii</i> un brevet antérieur <pays> <numero> <date></p> <p>(71) Déposant(s), y compris indications entre crochets [nationalité/État du domicile]</p> <p>(72) Inventeur(s)</p> <p>(74) Mandataire(s)/Représentant commun</p> <p>(75) Inventeur(s)/Déposant(s) (US seulement), y compris indications entre crochets [nationalité/État du domicile]</p> <p>(81) États désignés</p> | <p>Chacun des codes ci-dessous, figurant après la mention "Published/Publiée", indique que le texte en vis-à-vis a été publié sur la page de couverture de la brochure PCT:</p> <p>(a) Avec revendications modifiées.</p> <p>(b) Avec revendications modifiées et déclaration.</p> <p>(c) Avant l'expiration du délai prévu pour la modification des revendications, sera republiée si de telles modifications sont reçues.</p> <p>(d) Sur requête du déposant en vertu de l'article 64.3)c)i).</p> <p>(e) En vertu de l'article 643)c)ii) après publication d'un brevet basé sur la demande internationale ci-dessus et délivré par l'Office des brevets et des marques des États-Unis le <date> sous le numéro <numero>.</p> <p>(f) Avant l'expiration du délai mentionné à l'article 21.2)a), sur requête du déposant.</p> <p>(g) Sans classification; titre et abrégé non vérifiés par l'administration chargée de la recherche internationale.</p> <p>(h) Avec déclaration selon l'article 17.2)a). Sans classification et sans abrégé titre non vérifié par l'administration chargée de la recherche internationale.</p> <p>(i) Avec déclaration selon l'article 17.2)a). Sans abrégé titre non vérifié par l'administration chargée de la recherche internationale.</p> <p>(k) Avec une requête en rectification selon la règle 91.1.0.</p> <p>(in) Avec une indication relative à un micro-organisme déposé, fournie selon la règle 13^{bis}, séparément. et non avec la description.
Date de réception par le Bureau international: <date>.</p> <p>(n) Avec une déclaration relative à une divulgation non opposable ou à une exception au défaut de nouveauté.</p> <p>(p) Avec une indication relative à une revendication de priorité qui est considérée comme n'ayant pas été présentée.</p> |
|---|--|

CODES UTILISÉS POUR LA REPRÉSENTATION

DES NOMS DE LANGUE

(de la norme internationale ISO 639: 1988)

Code	Langue	Code	Langue
da	danois	ja	japonais
de	allemand	nl	néerlandais
en	anglais	no	norvégien
es	espagnol	ru	russe
fi	finnois	sv	suédois
fr	français	zh	chinois

SECTION I

PUBLISHED INTERNATIONAL APPLICATIONS

DEMANDES INTERNATIONALES PUBLIÉES

- (11) W098/34629 (13)A1
- (21) PCT1U598102535
- (22) 6 Feb/fh 1998 (06.02.1998)
- (25)en (26)en
- (31) 06/798,329 (32) 10 Feb/fév 1997 (33) US
(10.02.1997)
- (43)13 Aug/Août 1998(13.06.1998)
- (51)⁶ A61K 35/78, 39/385. 31135
- (54) PROCESS FOR PREPARING SYNTHETIC
SOIL-E(TRACT MATERIALS AND MEDICA-
MENTS BASED THEREON MATERIAUX
SYNTHÉTIQUES E(TRAITS DU SOL ET
MÉDICAMENTS À BASE DE CES
MATERIAUX
- (71) LAUB BIOCHEMICALS CORPORATION
tUS/USI; Suite 121. 1401 Qimil Street, Newport
Beach. CA 92660 (US).
- (72) LAUB, Richard, .I.: 154 Bsywciod Drive,
Newport Beach, CA 92660 (US).
- (74) ALTMAN, DaleI, K: Knobbe. Maileta. Olson and
Bear. LLP. 16th floor. 620 Newport Center Drive,
Newport Beach, CA 92660 (US).
- (81) AL AM AT AU AZ BA BB HG BR BY CA CM
CNCU~ZDEDKEEES FI OHOEGHOMOW I.IU
ID IL IS ii' KE KG KP KR KZ LC LK LR LS LI'
LU LV MD MG MK MN MW MX NO NZ PL
P1' RO RU SD SE SO SISK SL Ti TM TR T1'
UA UG liZ VN YU zw: A1' (01-I GM KE LS
MW SD SZ UG ZW); EA (AM AZ BY KG I~
MD RU Ti TM); EI' (AT BE CM DE DK ES FI
FR GB OR IE IT LU MC NL P1' SE); OA (HF
BJ CF CO CI CM OA GN ML MR NE SN TD
TO).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	(11) International Publication Number: WO 98/34629 A61K 35t78, 39/385, 31/35 (43) International Publication Date: 13 August 1998 (13.08.98)	AI
(21) International Application Number: PC1YUS98/02535	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, FE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SF, SG, SI, 5K, SL, TJ, TM, TR, TI, UA, UG, UZ, VN, YU, ZW, ARIPO patent 08/798,329 10 February 1997 (10.02.97) US (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IF, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 6 February 1998 (06.02.98)		
(30) Priority Data: TM, TR, TI, UA, UG, UZ, VN, YU, ZW, ARIPO patent 08/798,329 10 February 1997 (10.02.97) US (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IF, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).		
(71) Applicant: LAUB BIOCHEMICALS CORPORATION [US/US]; Suite 121, 1401 Quail Street, Newport Beach, CA 92660 (US).		
(72) Inventor: LAUB, Richard, I.; 154 Baywood Drive, Newport Beach, CA 92660 (US). With international search report.		
(74) Agent: ALTMAN, Daniel, F.; Knobbe, Martens, Olson and Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		

(54) Title: PROCESS FOR PREPARING SYNTHETIC SOIL-EXTRACT MATERIALS AND MEDICAMENTS BASED THEREON (57) **Abstract**

Phenolic polymers are prepared by dissolving one or more organic phenols along with sodium periodate in aqueous base at pH 8—11, and allowing the mixtures to stand between 35 and 80 °C for a period of 30 minutes to 100 hours. One or more inorganic Compounds or salts is added and the solution is allowed to stand at room temperature between 2 and 48 hours. Salt molecules as well as starting compounds and other low molecular—weight materials below about 500 to about 10,000 daltons are removed from the product solutions. Purified phenolic polymers are prepared in concentrated aqueous solution or in dried powder form in a final step if necessary. The resultant phenolic polymers exhibit physicochemical properties strongly resembling those of typical commercially—available natural soil extracts. The materials are active anti—viral and anti—microbial agents, and are effective in anti—viral amounts in blood product compositions, in methods for reducing or eliminating virus in blood products and in anti—viral and anti—microbial compositions for treating or preventing human or animal viral or microbial diseases.

**PROCESS FOR PREPARING
SYNTHETIC SOIL-EXTRACT MATERIALS
AND MEDICAMENTS BASED THEREON**

Field of the Invention

5 This invention relates to synthetic soil extract substances comprised of phenolic polymers, to the procedures for the preparation thereof, to the processes for the purification and isolation as aqueous solutions or dried powders of the synthetic materials, to compositions and methods for employing these synthetic phenolic polymers for reducing or eliminating viral activity in blood products, anti-viral
10 compositions for treating or preventing human or animal viral diseases and antimicrobial compositions for treating or preventing human or animal microbial diseases.

Background of the Invention

15 Soil extract materials, particularly the classes of substances known collectively as "humus," "humics," "humic acid(s)," or "humates," have been widely used in a number of applications for many years, as reviewed by F. J. Stevenson, *Humus Chemistry. Genesis Composition Reactions*; New York: Wiley, 1964; and, more recently, by A. Piccolo, *Humic Substances in Terrestrial Ecosystems*; New York: Elsevier, **1996**.

20 Natural and synthetic soil extracts have already been used extensively in horticultural and related industries, particularly as soil enhancement as well as soil remediation agents. In addition, natural and synthetic soil extracts have been employed as additives in organic gardening and landscaping; and in fresh-water aquaria. Some medicinal benefits have also been claimed for both synthetic- and
25 naturally-occurring soil extract substances.

 R. H. Faust, in a paper presented at the *Conference of the International Federation of Organic Agriculture Movements*; Copenhagen, Denmark: October, **1996**; P2, 20, has documented the benefits of humates in agriculture. In general, it has been found that humic materials can stimulate plant growth, including crop yield, by about 10-30%.

30 Soil extracts, and humic acid in particular, chelate a variety of metals. As a result, humic materials have been employed in soil remediation to remove heavy-metal, as reported by M. A.

Rashid, *Soil Sci.* 1971, *111*, 298-306. Humic acid has also been used to enhance the removal of aromatic hydrocarbons from aquifers contaminated with petroleum products: H. Xu, S. Lesage, L. Durham, and K. Novakowski, in *Proceedings of the Fourth Annual Symposium on Groundwater and Soil Remediation*; Calgary Alberta: September 21-23, 1994; 635-646; S. Lesage, H. Xu, K. S. Novakowski, S. Brown, and L. Durham, in *Proceedings of the Fifth Annual Symposium on Groundwater and Soil Remediation*; Toronto, Ontario: October 2-6, **1995**.

Humate materials have been used as poultry feed additives. Adding humate materials to the fodder of broiler chickens increases the yield mass on average by 5-7%, and also provides for a 3-5% gain in poultry safety: L. M. Stepchenko, L. V. Zhorina, and L. V. Kravtsova, *Biol. Nauki* 1991, *10*, 90-95.

T. A. Huck, N. Porter, and M. E. Bushell, *J. Gen. Microbiol.* **1991**, *137(10)*, 232 1-2329, have reported that soil isolates are effective media additives for the production of antibiotics, and that the extent of microbial growth stimulation can be quite large depending upon the species, the culture medium, and the environment. The use of selected batches of soil lignite humate as culture media for isolating thermophilic *Campylobacter* species extracts has also been documented by K. Weinrich, K. Winider, and E. Heberer, *DTW Dtsch. Tierarztl Wochenschr.* 1990, *97(12)*, 511-515. In addition, B. Grunda, *Zentralbl. Bakteriol. Parasitenkd Infektionskr. Hyg.* **1970**, *125(6)*, 584-593, has described the effects of humic acid on the count of soil microorganisms in culture.

Humates have long been used as folk remedies for a wide variety of illnesses (F. K. Achard, *Crells Chem. Ann.* 1786, *11*, 391-403), as recounted by T. D. Lotosh, *Biol. Nauki* 1991, *10*, 99-103. Humic acids isolated from peat exhibited significant efficacy for adhesions when tested on female rats that had standardized lesions placed on both uterine horns and the peritoneum of the anterior abdominal wall: M. Mesroglu, D. H. Mass, B.

Mauss, S. Plogmann, W. Ziechmann, and J. Schneider, *Zentralbl. Gynakol.* **1991**, *113(10)*, 583-590.

5 The ability of natural humic acid to affect anaphylactic sensitization and mast cell secretory function has been established by J. Wyczolkowska, T. Michon, Z. Slusarczyk, B. Kolago, and C. Maslinski, *Acta Pol. Pharm.* 1993, *50(6)*, 475-480. Humic substances in doses of 20 and 50 milligrams per kilogram body weight reduced histamine release from mouse peritoneal mast cells challenged with anti-IgE or concanavalin A in vitro.

10 Humic substances, including peats and sodium humates, are known to exhibit 10 anti-inflammatory properties: M. Kuhnert, V. Fuchs, and S. Golbs, *Arch. Exp. Veterinarmed.* 1982, *36(2)*, 169-177; S. B. Ye, J. Y. Chen, and Z. X. Zeng, *Ssu Chuan I Hsueh Yuan Hsueh Pao* 1985, *16(2)*, 127-129. Inflammatory states of the cervix, especially cervical erosion (known generally as cervicitis), can be treated with humic preparations: J. Woyton, M. Gabrys, T. Bielanow, M. Zinnmer, J. Sokalski, R. Geneja, and M. Zborowski, *Arch. immunol. Ther. Exp. (Warsz)* 1993, *41(1)*, 99-103.

15 Humic substances have been known to exhibit anti-microbial properties. Species for which natural as well as synthetic humic substances have been shown to be inhibitory include *C. albicans*, *Ent. cloacae*, *Prot. vulgaris*, *Ps. aeruginosa*, *S. typhimurium*, *St. aureus*, *St. epidermidis*, *Sir. pyo genes* (R. Ansorg and W. Rochus, *Arzneimittelforschung* 1978, *28(12)*, 2195-2198; *E. coli* and *Str. faecalis* were not affected), and *Str. mutans (sobrinus)* (Y. Nakamura, H. Kuwashima, S. Aoki, and T. Masuhara, *Shika Kiso Igakkai Zasshi* **1989**, *31(3)*, 329-332). Broadly speaking, concentrations in the range 50-2000 parts per million (ppm) are usually effective, yet are not cytotoxic: K. D. Thiel, B. Helbig, R. Klocking, P. Wutzler, M. Sprossig, and H. Schweizer, *Pharmazie* 1981, *36(1)*, 50-53.

20 Humic substances have long been known to exhibit anti-viral properties (H. Schultz, *Dtsch. Tierarztl. Wochenschr.* 1962, *69*, 613; **1965**, *72(13)*, 294-297; R Klocking and M. Sprossig, *Experientia* 1972, *28(5)*, 607-608), particularly retroviruses (G. Sydow, V. Wunderlich, R Klocking, and B. Helbig, *Pharmazie* 1986, *41(12)*, 865-30 868). Viral pathogens for which soil-extract materials have been shown to be effective include in particular Coxsackie virus A9 (Griggs-Baylor) (R. Klocking and

M. Sprossig, *Experientia* **1972**, *28*(5), 607-608), herpes simplex virus type 1 (B. T. Rouse (Ed.), *Herpes Simplex Virus*; Berlin: Springer-Verlag, 1992; R Klocking, K. D. Thiel, P. Wutzler, B. Helbig, and P. Drabke, *Pharmazie* **1978**, *33*(8), 539; F. Schiller, R. Klocking, P. Wutzler, and I. Farber, *Dermatol. Monatsschr.* **1979**, *165*(7), 505-509; B. Helbig, A. Sauerbrei, R. Klocking, P. Wutzler, N. Wicht, U. Wiedemaun, and G. Herrmann, *J. Med. Virol.* **1987**, *23*(3), 303-309; R. Klocking and B. Helbig, in *Humic Substances in the Aquatic and Terrestrial Environment*; Berlin: Springer-Verlag, 1991; 407-412;) and type 2 (anon. *Zentralbi. Bakteriol [Orig. A]* **1976**, *234*(2), 159-169; K. D. Thiel, R Klocking, H. Schweizer, and M. Sprossig, *Zentralbi. Bakteriol [Orig. A]* 1977, *239*(3), 304-321; K. D. Thiel, B. Helbig, R. Klocking, P. Wutzler, M. Sprossig, and H. Schweizer, *Pharmazie* 1981, *36*(1), 50-53; K. D. Thiel, B. Helbig, M. Sprossig, R. Klocking, and P. Wutzler, *Acta ViroL* **1983**, *27*(3), 200-208; K. D. Thiel, P. Wutzler, B. Helbig, R. Klocking, M. Sprossig, and H. Schweizer, *Pharmazie* 1984, *39*(11), 78 1-782); human immunodeficiency virus (HIV) (M.15 Cushman, P. Wang, S. H. Chang, C. Wild, E. De Clercq, D. Schols, M. E. Goldman, and J. A. Bowen, *J. Med Chem.* 1991, *34*(1), 329-337; M. Cushman, S. Kanamathareddy, E. De Clercq, D. Schols, M. E. Goldman, and J. A. Bowen, *J. Med Chem.* **1991**, *34*(1), 337-342; D. Schols, P. Wutzler, R Klocking, B. Helbig, and E. De Clercq, *J. Acquir. Immune Defic. Syndr.* **1991**, *4*(7), **677-685**; S. Loya, R. Tal, A. Hizi, S. Issacs, Y. Kashman, and Y. Loya, *J Nat. Prod* **1993**, *56*(12), 2120-2125; J. Schneider, R.. Weis, C. Manner, B. Kary, A. Werner, B. J. Seubert, and U. N. Riede, *Virology* **1996**, *218*(2), 389-395; influenza virus type A (Krasnodar/101/591H2N2) (R. Mentel, B. Helbig, R. Klocking, L. Dohner, and M. Sprossig, *Biomed Biochim. Acta* **1983**, *42*(10), **1353-1356**); and type B (J. Hils, A. May, M. Sperber, R. Klocking, B. Helbig, and M. Sprossig, *Biomed Biochim. Acta* **1986**, *45*(9), 1173-1179); as well as other respiratory tract infectious agents (A. Jankowski, B. Nienartowicz, B. Polanska, and A. Lewandowicz-Uszynska, *Arch. Immunol. Ther. Exp. (Warsz)* **1993**, *41*(1), 95-97).

The mechanism whereby humic substances inhibit the cytopathicity of a number of viruses has been studied in some detail. It is thought that the materials

prevent viral replicating by sorbing onto the viral envelope protein (gp120SU in the case of HIV) and thereby blocking the sorption of viral particles to cell surfaces: K. D. Thiel, R. Klocking, H. Schweizer, and M. Sprossig, *Zentralbi. Bakteriol. [Orig. A]* 1977, 239(3), 304-321; D. Schols, P. Wutzler, R. Klocking, B. Helbig, and E. De Clercq, *J. Acquir; Immune Def Syndr.* **1991**, 4(7), 677-685; anon., *Fortschr. Med.* **1995**, 113(7), 10; J. Schneider, R. Weis, C. Manner, B. Kary, A. Werner, B. J. Seubert, and U. N. Riede, *Virology* **1996**, 218(2), 389-395. Extracellular interception of pathogens by chemical agents that bind to them is a well-known means of immunological defense (D. M. Shankel, S. Kuo, C. Haines, and L. A. Mitscher, in *Antimutagenesis and Anticarcinogenesis Mechanisms III*; G. Bronzetti, H. Hayatsu, S. De Flora, M. D. Waters, and D. M. Shankel (Eds.); New York: Plenum, **1993**; 65-74). Such materials might well be termed “despathogens,” following the terminology proposed by T. Kada and K. Shimoi, *Bioessays* 1987, 7, 113-116, regarding “desmutagens.”

15 It has been reported that heat treatment of humic acids at 120 degrees Centigrade for 15 minutes does not alter their inhibitory effect on mutagens: T. Sato, Y. Ose, and H. Nagase, *Mutat. Res.* **1986**, 162(2), 173-178; T. Sato, Y. Ose, H. Nagase, and K. Hayase, *Sci. Total Environ.* 1987, 62(4), 305-310). That is, humic acids can be sterilized by autoclaving.

20 A direct comparison of enzymatic- with nonenzymatic-synthesized humic acid has shown that the latter is about a factor of ten more effective than the former for the treatment of herpes types 1 and 2: K. D. Thiel, P. Wutzler, B. Helbig, R. Klocking, M. Sprossig, and H. Schweizer, *Pharmazie* **1984**, 39(11), 78 1-782. Implanted bovine calcium hydroxyapatite is highly osteoconductive, and serves the host tissue as a “guideline” for the deposition of newly developing bone tissue. However, while it is well tolerated, it is resorbed only very slowly. Impregnation of the bovine hydroxyapatite with synthetic humic acid measurably stimulates the resorption process.

25 There is extensive covalent as well as hydrogen bonding of humic substances 30 to collagen fibers (with undoubted crosslinking as well), as determined by x-ray diffraction analysis: U. N. Riede, I. Jonas, B. Kim, U. H. Usener, W. Kreutz, and W.

Schlickewey, *Arch. Ort hop. Trauma Surg.* **1992**, *111(5)*, 259-264. Tendon strength is thereby increased by as much as 75 percent.

Natural as well as synthetic humic acids have been found to stimulate the phagocytic and bactericidal activity of granulocytes in humans at dose levels of 100-300 milligrams per day over a 14-day testing period: U. N. Riede, G. Zeck-Kapp, N. Freudenberg, H. U. Keller, and B. Seubert, *Virchows Arch. B Cell Pathol. Inci. Mol. Pathol.* **1991**, *60(1)*, 27-34; M. Kowalska, A. Denys, and J. Bialek, *Acta Pol. Pharm.* **1993**, *S0(4-5)*, 393-395. Of additional interest is the finding that dose levels of 600 milligrams per day caused only a transient and insignificant increase of phagocytic and bactericidal properties of the granulocytes.

The influence of natural as well as synthetic humic acids on haemostasis has been studied: H. P. Klocking, *Arch. Toxicol. Suppl.* **1991**, *14*, 166-169; W. Buczko, B. Malinowska, M. H. Pietraszek, D. Pawlak, and E. Chabielska, *Acta Pol. Pharm.* **1993**, *50(6)*, 507-511. It was found that humic acid in dose levels of 100-300 milligrams per kilogram body weight had no effect on bleeding time, clotting time, thrombin time, prothrombin time, kaolin-kephalin time, euglobulin lysis time, the concentration of fibrinogen, the platelet count, or ADP-induced platelet aggregation.

Various synthetic humic acids have been found to inhibit strongly the activity of purified lipoxygenase of rabbit reticulocytes, whereas prostaglandin H synthase of sheep vesicular gland is only weakly inhibited: C. Schewe, R. Klocking, B. Helbig, and T. Schewe, *Biomed Biochim. Acta* **1991**, *50(3)*, 299-305. The most effective humic acids were those derived from caffeic acid, 2,5-dihydroxytoluene, and 3,4-dihydroxytoluene.

The effect of natural humic acid on the regenerative response of liver tissue has been examined in rats submitted to two-thirds hepatectomy. The results were thought to be two-fold in nature. First, the short-term application of humic acid at a dose of 20 milligrams per kilogram body weight per day inhibited ornithine decarboxylase activity, as well as caused a decrease in spermidine formation and DNA and RNA, resulting in an overall decrease in liver restitution. In contrast, long-term application of humic acid resulted in the stimulation of ornithine decarboxylase, an increase in spermidine and histamine as well as RNA and DNA levels, and in overall liver mass.

The effects might be due at least in part to the humic-acid inhibition of polyamine biosynthesis: C. Maslinks, W. A. Fogel, and W. Andrzejewski, *Acta Pol. Pharm.* 1993, *50(4-5)*, 413-416.

5 Humic as well as fulvic acids extracted from peat have been shown to stimulate 5 respiration in rat liver mitochondria when present at concentrations of 40-3 60 micrograms per milliliter. Humic substances at concentrations of 40-400 micrograms per milliliter also increased the efficiency of oxidative phosphorylation in mitochondria in vitro, particularly after contact periods of over 1 hour: S. A. Visser, *Sci. Total Environ.* 1987, *62(4)*, 347-354.

10 Natural, synthetic, and commercial humic acids all have the ability to inhibit human plasmin activity: F. J. Lu and Y. S. Lee, *Sci. Total Environ.* **1992**, *114(4)*, 135-139. Thus, at a concentration of 20 micrograms per milliliter, each resulted respectively in residual plasmin activities of 70, 93, and 40 percent. Synthetic humic acids fabricated from caffeic acid and 3 ,4-dihydroxyphenylacetic acid have also been
15 found to raise the activity of plasminogen activator in isolated vascular preparations of pig ear (H. P. Kiocking, R. Klocking, and B. Helbig, *Farmakol. Toksikol.* 1984, *47(1)*, 93-95).

Peat-derived natural humic acids have been found to inhibit the hydrolysis of N-acetyl-L-tyrosine ethyl ester and N-benzoyl-L-leucine methyl ester by alpha-
20 chymotrypsin as well as by subtilisin: Sh. Zh. Zhorobekova and K. A. Kydraliev, *Biol. Nauki* **1991**, *10*, 151-154.

Sodium humate has been found to increase the lifespan of mongrel rats exposed to lethal doses of ⁶⁰Co -radiation, as reported by G. G. Pukhova, N. A. Druzhina,, L. M. Stepchenko, and E. E. Chebotarev, *Radiobiologiya* **1987**, *27(5)*, 650-653.

25 It has been found that naturally-occurring humic acid preparations can stimulate the production of cytokines, including interferon-gamma, interferon-alpha, and tumor necrosis factor-alpha (A. D. Inglot, J. Zielinksa-Jencylik, and E. Piasecki, *Arch. Immunol. Ther. Exp. (Warsz)* **1993**, *41(1)*, 73-80); and interferon-beta (Z. BlachOlszewska, B. Zaczynksa, E. Broniarek, and A. D. Inglot, *Arch. Immunol. Ther. Exp. (Warsz)*, **1993**, *41(1)*, 81-85).
30

Histopathological and ultrastructural studies have shown that naturally-occurring humic acids can cause morphological changes characteristic of thymus activity stimulation: J. A. Madej, J. Kuryszko, and T. Garbulinski, *Acta Pol. Pharm.* **1993**, *SO(4-5)*, 397-404.

5 It has been shown that incubation of cultured human umbilical vein endothelial cells either with natural or synthetic humic acid results in an enhanced cell surface expression of tissue factor activity. There are also changes in intracellular divalent calcium levels: H. L. Yang, F. J. Lu, S. L. Wung, and H. C. Chiu, *Thromb. Haemost.* **1994**, *71(3)*, 325-330.

10 Natural humic acid administered prophylactically to rats can decrease significantly the amount of gastric mucosa damage induced with ethanol. Humic acid also significantly accelerates the healing process of experimental-induced gastric and duodenal ulcers: T. Brzozowski, A. Dembinski, and S. Konturek, *Acta Pol. Pharm.* **1994**, *51(1)*, 103-107.

15 Humic acids have also been employed as veterinary medicine therapies, as described and discussed by M. Kuhnert, V. Fuchs, H. Knauf, and U. Knoll, *Arch. Exp. Veterinarmed* **1985**, *39(3)*, 344-349; and by M. Kuhnert, V. Fuchs, and S. Golb, *Dtsch. Tierarztl. Wochenschr.* **1989**, **96(1)**, 3-10. For example, H. Schultz, *Dtsch. Tierarztl. Wochenschr.* **1962**, **69**, **613**; **1965**, *72(13)*, 294-297, successfully employed peat mull to prevent the transmission of foot and mouth disease in pigs.

20 The pharmacokinetics of sodium humate in chickens have been studied extensively by J. HampI, I. Herzig, and J. VÍcek, *Vet. Med (Praha)*, **1994**, *39(6)*, 305-313. Free or liposome-encapsulated sodium humate was administered to chickens intracardially, orally, or subcutaneously and a number of pharmacokinetic parameters were then determined. The blood clearance of liposome-encapsulated sodium humate was higher than that of free sodium humate regardless of the manner of administration. On the other hand, the elimination half-life was longer after extravascular than after intracardial administration. Maximal drug concentration values indicated that the penetration of sodium humate from the injection site into

25

30 blood circulation is very slow. Biological availability of sodium humate also depended on the method of administration and dosage form. Aside from intracardial

administration, the highest bioavailability was found after subcutaneous administration of free sodium humate. Synthetic humic acid has been found to penetrate the dermis very quickly from a 1 percent water/oil emulsion, and to then form a reservoir in the horny layer: W. Wohlrab, B. Helbig, R. Klocking, and M. Sprossig, *Pharmazie* **1984**, 39(8), 562-564. Also, about 30 minutes after external application, concentrations of 1-3 percent of the total quantity applied are achieved, which percentage remains essentially unchanged thereafter.

The toxicity of naturally-occurring humic acids is remarkably low (K. D. Thiel, B. Helbig, R. Klocking, P. Wutzler, M. Sprossig, and H. Schweizer, *Pharmazie* **1981**, 36(1), 50-53; U. N. Riede, I. Jonas, B. Kim, U. H. Usener, W. Kreutz, and W. Schlickewey, *Arch. Ort hop. Trauma Surg.* 1992, 111(5), 259-264; H. Czyzewska-Szafran, Z. Jastrzebski, D. Soltysiak-Pawluczuk, M. Wutkiewicz, A. Jedrych, and M. Remiszewska, *Acta Pol. Pharm.* 1993, 50(4-5), 373-377; H. L. Yang, F. J. Lu, S. L. Wung, and H. C. Chiu, *Thromb. Haemost.* **1994**, 71(3), 325-330). [Cytotoxic effects of antiviral substances, including humic acids, are usually evaluated via biological (viability and alterations of cell morphology) and biochemical testing methods (⁵¹Cr release), as described by K. D. Thiel, U. Eichhorn, H. Schweizer, and R. Klocking, *Arch. Toxicol. Suppl.* **1980**, 4, 428-430.] The cytotoxicity (CD₅₀) of a naturally-occurring humic acid for human peripheral blood leukocytes (PBL) was found to be 1-9 milligrams per milliliter. In addition, J. Schneider, R. Weis, C. Manner, B. Kary, A. Werner, B. J. Seubert, and U. N. Riede, *Virology* **1996**, 218(2), 389-395, reported that the cytotoxicity of a synthetic humic acid prepared from hydroquinone for MT-2 cells was approximately 600 micrograms per milliliter. It has also been found that medicaments prepared from humic acids isolated from naturally-occurring soil materials are neither carcinogenic (Syrian hamster embryo cell transformation test: Koziorowska and E. Anuszevska, *Acta Pol. Pharm.* **1994**, 51(1), 101-102) nor mutagenic (T. Sato, Y. Ose, and H. Hagase, *Mutat. Res.* **1986**, 162(2), 173-178; V. M. Sui, A. I. Kiung, and T. I. Veidebaum, *Vopr. Kurortol. Fiozioter. Lech. Fiz. Kult.* **1986**, 2(3-4), 34-37; J. Koziorowska, B. Chlopkiewicz, and E. Anuszevska, *Acta Pol. Pharm.* **1993**, 50(4-5), 379-382). Prenatal (S. Golbs, V. Fuchs, M. Kuhnert, and C. Polo, *Arch. Exp. Veterinarmed* 1982, 36(2), 179-185) and embryotoxic and

teratogenic effects (T. Juskiewicz, M. Minta, B. Wlodarczyk, B. Biernacki, and J. Zmudzki, *Acta Pol. Pharm.* **1993**, 50(4-5), 383-388) are also not observed with humic preparations at daily dose levels from 5-50 milligrams per kilogram body weight. Topical preparations are tolerated even better (V. V. Soldatov and M. N. Cherepanova, *Vopr. Kurortol. Fizioter. Lech. Fiz. Kult.* **1970**, 35(3), 256-259; H. CzyzewskaSzafran, Z. Jastrzebski, D. Soltysiak-Pawluczuk, M. Wutkiewicz, A. Jedrych, and M. Remiszewska, *Acta Pol. Pharm.* **1993**, 50(4-5), 373-377) when applied dermally in aqueous solution in amounts as high as 10 percent weight-by-volume (K. Wiegleb, N. Lange, and M. Kuhnert, *Dtsch. Tierarztl. Wochenschr.* **1993**, 100(10), 412-416).

Soil extracts, including humics, are quite complex mixtures of organic and inorganic polymeric compounds whose composition varies widely depending upon the source of the soil and the method(s) of extraction and subsequent treatment: D. Vaughan and R. E. Malcolm, *Plant Soil Sci.* **1985**, 16, 1-443 (see also N. Senesi, Y. Chen, and M. Schnitzer, *Soil Bid. Biochem.* **1977**, 9, 397-403).

Techniques used for the chemical characterization of soil extracts, including humics, have included capillary electrophoresis (S. Pompe, K. Heise, and H. Nitsche, *J. Chromatogr. A*, **1996**, A 723(1), 215-218), ultracentrifugation (R. S. Cameron, B. K. Thornton, R. S. Swift, and A. M. Posner, *J. Soil Sci.* **1972**, 23(4), 394-408; A. E. Wilkinson, J. J. Higgo, and M. N. Jones, *Biochem. Soc. Trans.* **1991**, 19(4), 414S), electron paramagnetic resonance and infrared spectroscopy (G. Tollin and C. Steelink, *Biochim. Biophys. Acta*, **1966**, 112(2), 3 77-379), various solvent and other fractionation methods (R. S. Cameron, B. K. Thornton, R. S. Swift, and A. M. Posner, *J. Soil Sci.* **1972**, 23(4), 394-408; C. E. Clapp, M. H. Hayes, and R. S. Swift; *Agricultural Research Service Report Number 0000042025*; M. H. Hayes, R. L. Malcolm, and C. E. Clapp, *Agricultural Research Service Report Number 000004203S*; I. Csiky, G. Marko-Varga, and J. A. Jonsson, *Anal Chim. Acta* **1985**, 178, 307-312; J. A. Amador, P. J. Milne, C. A. Moore, and R. G. Zika, *Mar. Chem.* **1990**, 29, 1-17), gas chromatography (I. Arsenie, H. Boren, and B. Allard, *Sci. Total Environ.* **1992**, 116(3), 213-220), gas chromatography-mass spectrometry (H.-R. Schulten and M. Schnitzer, *Soil Sci.* **1992**, 153(3), 205-224; G. Chiavari, G. Torsi, D. Fabbri, and G. C. Galletti, *Analyst (London)* **1994**, 119(6), 1141-1150), gel-permeation

chromatography (B. Kosinkiewicz, *Acta Microbiol. Pol.* **1977**, *26(4)*, 387-392; 5.
Mon, M. Hiraide, and A. Mizuike, *Anal. Chim. Acta* **1987**, *193*, 231-238), high-
performance liquid chromatography (M. A. Curtis, A. F. Witt, S. B. Schram, and L.
B. Rogers, *Anal. Chem.* **1981**, *53*, 1195-1199; K. Ravichandran, J. J. Lewis, I. H. Yin,
5 M. Koenigbauer, C. R. Powley, P. Shah, and L. B. Rogers, *J. Chromatogr.* **1988**,
439, 213-226; J. Knuutinen, L. Virkki, P. Mannila, P. Mikkelsen, J. Paasivirta, and
S. Herve, *Wat. Res.* 1988, *22(8)*, 985-990, M. Susic and K. G. Boto, *J.*
Chromatogr. 1989, *482(1)*, 175-187), mass spectrometry (H.-R. Schulten, G. Abbt-
Braun, and F.H. Frimmel, *Environ. Sci. Technol.* 1987, *21(4)*, 349-357; C. Sorge, R.
10 Mueller, P. 10 Leinweber, and H. R. Schulten, *Fresenius' J. Anal. Chem.* 1993,
346(6-9), 697-703; M. Remmler, A. Georgi, and F.-D. Kopinke, *Eur. Mass Spectrom.*
1995, *1(4)*, 403-407), nuclear magnetic resonance (F. J. Vila, H. Lentz, and H. D.
Ludemann, *Biochem. Biophys. Res. Commun.* 1976, *72(3)*, 1063-1070; G. Almendros,
R. Frund, F.J. Gonzalez-Vila, K. M. Haider, H. Knicker, and H. D. Ludemann, *FEBS*
15 *Lett.* 15 1991, *282(1)*, 119-121), and polyacrylamide gel electrophoresis (R.
Klocking, *J. Chromatogr.* 1973, *78*, 409-416; L. P. Glazkova, V. S. Ulashehik, and F.
A. Puntus, *Vopr. Kurortol. Fizioter. Lech. Fiz. Kult.* 1984, *2(2)*, 2 1-24).

Very many studies have been carried out on the structural characterization of
soil extracts, including humic acid, by reductive degradation, as reviewed by L. B.
20 Sonnenbeng, Ph.D. Thesis, University of North Carolina at Chapel Hill, 1989:
Dissertation Services Order No. 9007318. Models of humic structure based on the
physicochemical properties of membranes have also been developed by R. L.
Wershaw, *Environ. Health Perspect.* 1989, *83(11)*, 19 1-203. R. R. Engebretson and R.
von Wandruszka, *Environ. Sci. Technol.* **1994**, *28*, 1934, have described efforts at
25 characterizing the micro-organization of dissolved humic acids in terms of their
secondary structure, that is, on the way in which these large molecules arrange
themselves in three dimensions in solution. The molecules are thought to be dendritic,
that is, are hyperbranched fractal-like structures that emanate somewhat like the
spokes of a wagon-wheel from a central core, and which contain a large number of
30 carboxyl and hydroxyl terminal groups: T. H. Mourey, S. R. Turner, M. Rubinstein, J.
M. J. Frechet, C. J. Hawker, and K. L. Wooley, *Macromolecules* **1992**, *25*, 240 1-2406.

Cluster aggregates of humic acid have an average diameter of 700-1700 Angstroms; large clusters have a fractal dimension of 2.3: R. Osterberg and K. Mortensen, *Radiat. Environ. Biophys.* **1994**, 33(3), 269-276

Because humic substances are not chemically well-defined, the preparation of synthetic humic acids whose physicochemical properties mimic naturally-occurring materials is quite difficult, as pointed out by K. Murray and P. W. Linder, *J. Soil Sci.* 1983, 34, 511-523. Nevertheless, there have been several notable advances in this area. Broadly speaking, three general strategies have evolved. All depend upon starting with well-defined molecules of molecular weight on the order of hydroxybenzoic acid, and then causing the molecules to polymerize upon themselves to form larger molecules. The methods differ in the causation factor, which can be microbial, chemical, or enzymatic.

Humic acids of microbial origin have been described and discussed by M. Robert-Gero, C. Hardisson, L. Le Borgne, and G. Pignaud, *Ann. Inst. Pasteur (Paris)* **1966**, 111(6), 750-767; and by M. Robert-Gero, C. Hardisson, L. Le Borgne, and G. Vidal, *Ann. Inst. Pasteur (Paris)* **1967**, 113(6), 903-909.

The chemical synthesis of humic acids has been pioneered by R. Klocking, B. Helbig, and associates: R Klocking, B. Helbig, and P. Drabke, *Pharmazie* 1977, 32, 297; R. Klocking, B. Helbig, K. D. Thiel, T. Blumohr, P. Wutzler, M. Sprossig, and F. Schiller, *Pharmazie* **1979**, 34(5-6), 293-294; R. Mentel, B. Helbig, R. Klocking, L. Dohner and M. Sprossig, *Biomed Biochim. Acta* **1983**, 42(10), 1353-1356; H. P. Klocking, R. Klocking, and B. Helbig, *Farmakol. Toksikol.* **1984**, **47(1)**, 93-95; K. D. Thiel, P. Wutzler, B. Helbig, R. Klocking, M. Sprossig, and H. Schweizer, *Pharmazie* 1984, 39(11), 78 1-782; J. Hils, A. May, M. Sperber, R. Klocking, B. Helbig, and M. Sprossig, *Biomed. Biochim. Acta* **1986**, 45(9), 1173-1179; B. Helbig, A. Sauerbrei, R. Klocking, P. Wutzler, N. Wicht, U. Wiedemann, and G. Herrmann, *J. Med Virol.* 1987, 23(3), 303-309; K. I. Hanninen, R. Klocking, and B. Helbig, *Sci. Total Environ* **1987**, 62, 201-2 10; R. Klocking and B. Helbig, in *Humic Substances in the Aquatic and Terrestrial Environment*; New York: Springer-Verlag, **1989**; 407-412; C. Schewe, R. Klocking, B. Helbig, and T. Schewe, *Biomed Biochim. Acta* **1991**, 50(3), 299-305; D. Schols, P. Wutzler, R. Klocking, B. Helbig, and E. De Clercq, *J. Acquir. Immune*

Defic. Syindr. **1991**, 4(7), 677-685. Typically, 10 millimoles of the starting small-molecule phenolic compound is dissolved in distilled water, the pH is adjusted to 8.5 with aqueous sodium hydroxide (NaOH), and then 2-5 millimoles of sodium periodate (NaIO₄) is added. The solution is warmed at 50⁰C for 30 minutes, and is then allowed to stand overnight. The resultant humic acid-like polymeric products are isolated by precipitation with lead(II) nitrate [Pb(NO₃)₂]. The precipitated polymers are redissolved in aqueous sodium hydroxide (pH 8.5) and heated with 8-hydroxyquinoline for 30 minutes at 100⁰C. The precipitate formed is lead(II) chelate, which is removed by filtration. Residual 8-hydroxyquinoline is extracted with chloroform, and the desired polymeric material is then precipitated from the aqueous solution by the addition of various combinations of acetic acid, ethyl acetate, and ethanol. Starting compounds that have been used for the synthesis of humic-like materials include 4-[bis(p-hydroxyphenyl)methylene]-2,5-cyclohexadien-1-one (*aurin*) 4-[bis(3-carboxy-4-hydroxyphenyl)methylene]-2-carboxy-2,5-cyclohexadien-1-one (*aurintricarboxylic acid*), 3-(3,4-dihydroxyphenyl) propenoic acid (*caffeic acid*), 1,2-dihydroxybenzene (*catechol*), 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxyphenyl) propenoate (*chlorogenic acid*), 3,4-dihydroxyphenylacetic acid (*homoprotocatechuic acid*), 1-(3,4-dihydroxyphenyl)-2-(N-methylamino) ethanol (*epinephrine*), 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid (*ferulic acid*) 3,4,5 trihydroxybenzoic acid (*gallic acid*), 2,5-dihydroxybenzoic acid (*gentisic acid*), 2,5-dihydroxyphenylacetic acid (*homogentisic acid*), 3-(3,4-dihydroxyphenyl) propionic acid (*hydrocaffeic acid*), 1,4-dihydroxybenzene (*hydroquinone*), 2,3-dihydroxytoluene (*3-methylcatechol*), 3,4-dihydroxytoluene (*4-methylcatechol*), 2,5-dihydroxytoluene (*2-methylhydroquinone*), 4,4'-(2,3-dimethyltetramethylene)-di-(1,2-dihydroxybenzene) (*nordihydroguaiaretic acid*), 1-(3,4-dihydroxyphenyl)-2-aminoethanol (*norepinephrine*), 3,4-dihydroxybenzoic acid (*protocatechuic acid*), 1,2,3-trihydroxybenzene (*pyrogallol*), 1,3-dihydroxybenzene (*resorcinol*), and 4-hydroxy-3-methoxybenzoic acid (*vanillic acid*). Other notable efforts on the chemical synthesis of humic-like substances include the studies by De Clercq and colleagues on aurintricarboxylic acid, its derivatives, and related compounds: M. Cushman, P. Wang, S. H. Chang, C. Wild, E. De Clercq, D. Schols, M. E. Goldman, and J. A. Bowen, *J.*

Med Chem. **1991**, *34(1)*, 329-337; M. Cushman, S. Kanamathareddy., E. De Clercq, D. Schols, M. E. Goldman, and J. A. Bowen, *J. Med Chem.* **1991**, *34(1)*, 337-342. Related efforts have also been reported by M. Robert-Gero, C. Hardisson, L. Le Borgne, and G. Vidal, *Ann. Inst. Pasteur (Paris)* **1967**, *113(6)*, 903-909; M. Jakubiec, E. Miszczak, and J. Szczerkowska, *Acta Microbiol. Pol. [B]* **1971**, *3(1)*, 63-66; R. Ansorg and W. Rochus, *Arzneimittelforschung* **1978**, *28(12)*, 2195-2198; J. Pommery, M. Imbenotte, A. F. Urien, D. Marzin, and F. Erb, *Mutat. Res.* **1989**, *223(2)*, 183-189; F. J. Lu and Y. S. Lee, *Sci. Total Environ.* **1992**, *114*, 135-139; K. Wiegleb, N. Lange, and M. Kuhnert, *DTW Dtsch. Tierarztl. Wochenschr.* **1993**, *100(10)*, 412-416; H. L. Yang, F. J. Lu, S. L. Wung, and H. C. Chiu, *Thromb. Haemost.* **1994**, *71(3)*, 325-330; W. Seffner, F. Schiller, R. Heinze, and R. Breng, *Exp. Toxicol. Pathol.* **1995**, *47(1)*, 63-70; and J. Schneider, R. Weis, C. Manner, B. Kary, A. Werner, B. J. Seubert, and U. N. Riede, *Virology* **1996**, *218(2)*, 389-395.

The enzymatic catalytic synthesis of humic acids dates to about 1961 with the work by R. E. Hampton and R. W. Fulton, *Virology* **1961**, *13*, 44-52 (see also R. E. Hampton, *Phytopathology* **1970**, *60*, 1677-1681), who found that enzymatically oxidized phenols inactivate phytopathogenic (i.e., plant-related) viruses. Typically odiphenol oxidase has been employed for the enzymatic synthesis of humic-like materials: anon. *Zentralbi. Bakteriol. [Orig. A]* **1976**, *234(2)*, 159-169; R Klocking, B. Helbig, and P. Drabke, *Pharmazie* **1977**, *32(5)*, 297; K. D. Thiel, B. Helbig, R. Klocking, P. Wutzler, M. Sprossig, and H. Schweizer, *Pharmazie* **1981**, *36(1)*, 50-53; K. D. Thiel, B. Helbig, M. Sprossig, R. Klocking, and P. Wutzler, *Acta Virol.* **1983**, *27(3)*, 200-208; K. D. Thiel, P. Wutzler, B. Helbig, R. Klocking, M. Sprossig, and H. Schweizer, *Pharmazie* **1984**, *39(11)*, 781-782; and G. Sydow, V. Wunderlich, R Klocking, and B. Helbig, *Pharmazie* **1986**, *41(12)*, 865-868.

A direct comparison of humic acids synthesized enzymatically and nonenzymatically from caffeic and hydrocaffeic acids has shown that the two synthetic routes produce materials that differ somewhat in their efficacy for the suppression of herpes (hominis) types 1 and 2 viruses: K. D. Thiel, P. Wutzler, B. Helbig, R. Klocking, M. Sprossig, and H. Schweizer, *Pharmazie* **1984**, *39(11)*, 781-782.

German patent DE 3830333 C1 (15 March 1990) issued to Wagner discloses a pharmaceutical composition comprised in part of humic acid for the topical treatment of herpes virus-induced vesicular rash. The method of preparation of the humic acid utilized is not disclosed.

5 U.S. patent 4,999,202 (12 March 1991) issued to Cronje, et al discloses a composition that has bactericidal or bacteriostatic properties, and which comprises oxidized coal-derived humic acid or a salt or derivative thereof as the active ingredient in a suitable carrier. The active ingredient is preferably an alkali metal salt of coal-derived humic acid and the carrier is preferably water. The method of
10 preparation involves recovery of the humic acid by precipitation, after acidification with an acid such as hydrochloric acid to a pH value of 2.

European patent application 0537430A1 (21 April 1993) from Riede, et al. discloses the use of natural or synthetic, modified or unmodified ammonium or alkali metal humates against viruses, especially against retroviruses such as HIV.
15 Riede et al. disclose humates that have insignificant toxicity and are neither mutagens nor teratogens. Riede, et al. also disclose a specific synthetic preparation of said humates that requires as long as 10-15 days to complete the oxidation of the starting material during which time the reaction temperature is maintained below 40°C. The solution is acidified to pH 4-5 following the synthesis, following which
20 known methods of purification, such as preparative chromatography, ultrafiltration, centrifugation, or electro dialysis, are employed. No inorganic salts other than the oxidant or the starting material are employed during or after the synthesis.

World patent application 95/08335 (published 30 March 1995) from Zanetti, which is equivalent to U.S. application 08/3 10,675 (filed 22 September 1994) discloses
25 a method of inhibiting human immunodeficiency virus infection that comprises contacting leukocytes, peripheral blood mononuclear cells, and lymphocytes of an individual infected with said virus with an anti-immunodeficiency virus amount of a natural, commercially available preparation of humic acid. Synthetic humic acid preparations are also disclosed. The synthetic procedure disclosed employs no
30 inorganic salts other than sodium periodate for the oxidation of the starting material. The synthetic procedure employs acidification of the product of the synthesis with 6

M HCl to a pH of less than 1. This solution is allowed to stand overnight. A precipitate of the synthetic product forms which is washed several times with 1 M HCl. The final step involves freeze drying the precipitate.

5 Phenolic polymers such as humic acid, when exposed to hydrochloric acid 5 under the above conditions as well as the conditions in Cronje '202, may be chlorinated. That is, one or more chlorine atoms will possibly be added to the aromatic rings of the phenolic polymers: R. B. Wagner and H. D. Zook, *Synthetic Organic Chemistry*, New York: J. Wiley & Sons, March 1963, 88-147. Other changes such as selective 0-demethylation of humic acid products may also occur in 10 the presence of hydrochloric acid: M. Fieser and L. F. Fieser, *Reagents For Organic Synthesis*, New York, Wiley-Interscience, Vol. 4, 1974, 250. It has been reported that aqueous chlorination of humic acids results in the formation of compounds with direct-acting mutagenic activity in the Ames/Salmonella plate assay. Nonchlorinated humic acids are not mutagenic: J.R. Meier, RD. Lingg, RJ. Bull, 15 *Mutat. Res.*, **1983**, 118(1-2), 25-41. It has also been reported that freeze-dried, chlorinated humic acid contains nonvolatile, direct-acting mutagenic and/or alkylating agents: S.C. Agarwal, J. Neton, *Sci. Total Environ.*, **1989**, 79(1), 69-83. A subchronic 90-day toxicology study has been conducted with chlorinated and nonchlorinated humic acids using male Sprague-Dawley rats. Increased incidence and severity of hematuria was found in the 1.0-g/l chlorinated humic acid group: 20 L.W. Condie, RD. Laurie, J.P. Bercz, *J. Toxicol. Environ. Health*, **1985**, 15(2), 305-14. Thus, synthetic methods for the production of humic acids that can possibly produce chlorinated humic acids are to be avoided.

25 Another area of related art relevant to this invention is comprised of blood product compositions and methods for treating blood products to reduce viral and microbial activity. A variety of human blood products including blood platelets exist to meet critical medical therapeutic needs. Viral safety depends upon donor selection and screening. It has proven to be impossible to date to screen blood products adequately to provide complete assurance that there is no viral contamination. These 30 blood products may be inadvertently contaminated with viruses such as HIV-human immunodeficiency virus, hepatitis virus, including hepatitis A, B, and C and other

viruses. A solvent/detergent (SD) technique exists for treating blood products including blood platelets, but this technique is primarily limited to lipid enveloped viruses and is known to be ineffective for nonenveloped viruses such as hepatitis A, parvovirus B19 and picornaviruses: P. M. Mannucci, et al., *Ann. Intern. Med.*, **1994**, 120(1),1-7; and L. Gurtler, *Infusionsther. Transfusionsmed.*, **1994**, 21(Suppl 1), 77-9. Additionally, it is necessary to separate the detergents in the SD method from the blood product utilizing extraction with soybean or castor oil and chromatography on insolubilized Cl 8 resin: B. Horowitz et al., *Blood*, 1992, 79(3), 826-31; and Y. Piquet et al., *Vox Sang.*, 1992, 63(4), 251-6.

10 A pasteurization process has been developed for treating blood products. This involves heat treatment of a stabilized aqueous protein solution at 60°C for 10 hours. However, residual infectious hepatitis A virus has been found even after 10 hour heat treatment of the stabilized preparation: J. Hilfenhaus and T. Nowak, *Vox Sang.*, **1994**, 67(Suppl 1), 62-6. Neither the solvent/detergent (S/D) process nor the pasteurization process
15 alone are adequate to inactivate viruses that are strongly resistant to heat and organic solvents. In this context, human parvovirus B19 and hepatitis A virus are of particular concern: H. Schwinn et al., *Arzneimittelforschung*, **1994**, 44(2), 188-91.

A final super heat treatment (**100° C** for 30 min) has been developed as an additional virus inactivation step to improve the safety of plasma derived factor VIII (FVIII) concentrate already treated with the solvent/detergent (S/D) method during the manufacturing process. The efficiency of the super heat treatment was demonstrated in inactivating two nonlipid enveloped viruses (Hepatitis A virus and Poliovirus 1). However, the loss of FVIII procoagulant activity during the super heat treatment was about 15%, estimated both by clotting and chromogenic assays: S. Arrighi et al.,
20 *Thromb. Haemost.*, **1995**, 74(3), 863-73.

A method for treating human blood products employing short wavelength ultraviolet light (UVC) irradiation for virus inactivation and enhancement of its compatibility with proteins by quenchers of reactive oxygen species has been developed. However, blood protein recovery was typically only around 75%: S. Chin et al.,
30 *Blood*, 1995, 86(11), 433 1-6. Ultraviolet irradiation methods have additionally

been reported not to be applicable to cellular blood products: C. M. Allen, *Photochem. Photobiol.*, **1995**, 62(1), 184-9.

In summary, there remains a need for a safe, efficacious and simple method for treating all human blood products to reduce or eliminate lipid enveloped and nonenveloped virus activity without loss of blood product or blood product activity.

The diversity of physicochemical characteristics as well as wide variation in the biological activity and toxicity of humics extracted or otherwise derived from natural soils has been well documented. This diversity and variation is due to variations in factors such as the source of soil, the method(s) of extraction and/or isolation and the technique(s) employed to treat the extract once it has been separated and isolated from crude soil. The consequence of irreproducibility of properties of substances extracted from natural soil is that the commercial value of such materials is minimized. In addition, they are rendered unsuitable as medicaments. Also, while a number of laboratory-scale processes have already been described that address various aspects of the isolation, synthesis, and/or preparation of humic substances or similar materials, there are no reports of preparing and isolating such purely synthetic humic acids or similar materials by methods that are suitable for scaleup directly to industrial levels, that provide economically acceptable yields, and that optimize the preparation procedures from the standpoint of medicament safety and efficacy. All of the known synthetic methods utilize potentially toxic precipitation methods (lead(II) nitrate precipitation) followed by complex isolation procedures, potentially mutagenic compound-producing hydrochloric acid precipitation or lengthy synthetic steps as long as 10 days. The solution is to devise simple synthetic procedures that yield inexpensive, safe materials whose physicochemical attributes are reproducible, and that at least simulate those of typical commercially-available soil extracts. This invention is directed to this solution and to compositions and methods employing synthetic materials prepared according to the process of the invention.

Summary of the Invention

One aspect of the invention is a process for preparing synthetic phenolic polymeric materials whose physicochemical properties and attributes are reproducible, and which simulate the physicochemical properties and attributes of typical

commercially-available natural humic acids and other soil extracts. This process comprises the steps of:

5 a) dissolving one or more starting organic compounds selected from the group consisting of the compounds listed in Table 1 and Table 2 in an aqueous solution comprising distilled water or sodium hydroxide;

b) adjusting the pH of the aqueous solution resulting from step a) to between 8 and 11 if necessary;

c) adding an alkaline periodate salt or alkaline-earth periodate salt to the aqueous solution resulting from step b);

10 d) maintaining the temperature of the solution resulting from step c) between 35 and 80⁰C for a period of 30 minutes to 100 hours;

e) adding one or more compounds or salts selected from the group consisting of boric acid, borate salts, alkaline earth salts, transition metal salts, alkaline sulfides, alkaline earth sulfides or transition metal sulfides to the aqueous solution resulting from step d);

15 f) allowing the aqueous solution resulting from step e) to stand with or without stirring at room temperature between 2 and 48 hours;

g) removing molecules from the solution resulting from step f) below about 500 to about 10,000 daltons;

20 h) concentrating the solution resulting from step g); and

i) removing the water from the solution resulting from step h) if necessary.

In one embodiment of the process, the pH of the aqueous solution resulting from step a) is adjusted to between 8 and 11 by adding aqueous ammonium hydroxide, or other aqueous alkaline oxide or hydroxide, or aqueous alkaline-earth oxide or hydroxide, or aqueous transition-metal oxide or hydroxide, or hydrochloric acid or other inorganic acid. In another embodiment of the process, the alkaline or alkaline-earth sulfides are added to the solution resulting from step b). Alternatively, the alkaline or alkaline-earth sulfides are added to the solution resulting from step c). In another embodiment of the process, transition-metal sulfides are added to the solution resulting from step b). Alternatively, transition-metal sulfides are added to the solution resulting from step

c). In another embodiment of the process, any precipitate formed from the solution resulting from step f) is removed by centrifugation. In another embodiment of the process, step g) is accomplished by dialyzing the solution resulting from step f) with a flow-through apparatus consisting of a sandwich-type membrane of molecular-weight cutoff of 500-10,000 daltons until the conductivity of the retentate solution has dropped to 200 microsiemens or less. In a further embodiment of the process following dialysis in step g), the solution resulting from step g) is concentrated in step h) by utilizing a flow-through dialysis apparatus that produces a retentate solution such that the volume of the dialysis apparatus retentate solution is allowed to drop. In another embodiment of the process, the solution resulting from step g) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution. In another embodiment of the process, the solution resulting from step g) is autoclaved between 100 and 1500 C for 5 to 60 minutes to produce a sterile solution. In another embodiment of the process, the solution resulting from step h) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution. In another embodiment of the process, the solution resulting from step h) is autoclaved between 100 and 150° C for 5 to 60 minutes to produce a sterile solution. In another embodiment of the process, mannose or other static electricity reduction material is added to the solution resulting from step h) prior to removing the water from said solution in step i). In another embodiment of the process, step i) is accomplished by spray-drying or thermally-induced evaporation or vacuum or freeze-drying. In another embodiment of the process, the dried powder from step i) is autoclaved between 100 and 150°C for 5 to 60 minutes to produce a sterile powder. In another embodiment of the process, tubular, capillary, coiled-spiral, or plane dialysis membranes are used in step g) for removing molecules from the solution resulting from step f). In a further embodiment of the process employing tubular, capillary, coiled spiral, or plane dialysis membranes in step g), the solution resulting from step g) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution. Alternatively, the solution resulting from step g) which employed tubular, capillary, coiled-spiral, or plane dialysis emembranes is autoclaved between 100 and 150° C for 5 to 60 minutes to produce a sterile solution. In a further embodiment of the process employing

tubular, capillary, coiled-spiral, or plane dialysis membranes in step g), the solution resulting from step g) is concentrated in step h) by utilizing a flow-through dialysis apparatus that produces a retentate solution such that the volume of the dialysis apparatus retentate solution is allowed to drop. In another embodiment of the process

5 of the invention, the solution resulting from step g) is further dialyzed with a flow-through apparatus consisting of a sandwich-type membrane of molecular-weight cutoff of 30,000-100,000 daltons to produce an aqueous filtrate solution containing synthetic phenolic polymeric materials of lower molecular weight between 500 and 10,000 daltons and upper molecular weight between 30,000 and 100,000 daltons. In a further embodiment of the prior process employing further dialysis, tubular, capillary, 10 coiled spiral, or plane dialysis membranes are used for said further dialysis. In a further embodiment of the prior process employing tubular, capillary, coiled spiral, or plane dialysis membranes in step g), the solution resulting from step g) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution. 15 Alternatively, the solution resulting from step g) which employed tubular, capillary, coiled-spiral, or plane dialysis membranes is autoclaved between 100 and 150° C for 5 to 60 minutes to produce a sterile solution. In a further embodiment of the previous process employing tubular, capillary, coiled-spiral, or plane dialysis membranes in step g), the solution resulting from step g) is concentrated in step h) by utilizing a 20 flow through dialysis apparatus that produces a retentate solution such that the volume of the dialysis apparatus retentate solution is allowed to drop.

In another aspect of the invention, a blood product composition is provided comprising an anti-viral amount of a synthetic phenolic polymeric material produced by the process of the invention combined with a blood product. In one embodiment of 25 the blood product composition, said blood product is whole human blood. In another embodiment of the blood product composition, said blood product is human blood platelets. In another embodiment of the human blood platelet blood product composition, the anti-viral amount is an amount sufficient to reduce human immunodeficiency virus (HIV) activity. In yet another embodiment of the human 30 blood platelet blood product composition, the anti-viral amount is an amount sufficient to reduce non-enveloped virus activity. Preferably, the non-enveloped virus is

parvovirus or cytomegalovirus. In another embodiment of the blood product composition, said blood product is human blood serum. In another embodiment of the blood product composition, said blood product is a human blood protein. Preferably, said human blood protein is human serum albumin or human serum gamma-globulin.

5 In another embodiment of the blood product composition, said blood product is a human haemophilia factor. Preferably, the human haemophilia factor is factor VIII or factor IX. In a further embodiment of the blood product composition wherein said blood product is a human haemophilia factor, the anti-viral amount is sufficient to reduce human immunodeficiency virus (HIV) activity. Alternatively, the anti-viral amount is sufficient to reduce non-enveloped virus activity. Preferably, the non-

10 enveloped virus is parvovirus or cytomegalovirus.

In yet another aspect of the invention, there is provided a method of reducing the amount of virus in a blood product by contacting said blood product with an anti-viral amount of a synthetic phenolic polymeric material produced by the process of the invention. In one embodiment of the method of reducing the amount of virus in a

15 blood product, said contacting consists of sterily breaking a seal in a connecting path between two separate chambers, one of which contains said blood product in a sterile form and the other of which contains said anti-viral amount of said synthetic phenolic polymeric material in sterile form. In another embodiment of the aforementioned

20 method, said contacting consists of injecting a sterile solution containing said anti-viral amount into said blood product. In another embodiment of the method above, said virus is preferably Human Immunodeficiency Virus (HIV). In another preferred embodiment of the above method, said virus is Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, parvovirus, or cytomegalovirus. In another embodiment of the

25 above method, one or more additional blood treatment methods for reducing viral activity are employed. Preferably, the additional blood treatment method is the solvent/detergent (SD) method.

In a further aspect of the invention, there is provided a composition for treating or preventing human or animal diseases caused by a virus comprising an anti-viral

30 amount of a synthetic phenolic polymeric material produced by the process of the invention and at least one physiologically acceptable carrier or excipient. Preferably,

the virus is Human Immunodeficiency Virus (HIV), Herpes Simplex Virus Type I or Type II, or is a picornavirus. Preferably, the physiologically acceptable carrier or excipient is an injectable solution excipient, a topical formulation excipient, an ingestable excipient, a nasal spray excipient, a metered-dose inhaler excipient, vaginal or anal suppository excipient, or an excipient suitable for disinfection or preservation of a medical device. Still another aspect of the invention provides a composition for treating or preventing human or animal microbial-induced diseases comprising an antimicrobial amount of a synthetic phenolic polymeric material produced by the process of the invention and at least one physiologically acceptable excipient. Preferably, the physiologically acceptable carrier or excipient is an injectable solution excipient, a topical formulation excipient, an ingestable excipient, a nasal spray excipient, a metered-dose inhaler excipient, vaginal or anal suppository excipient, or an excipient suitable for disinfection or preservation of a medical device. Preferably, the medical device is a contact lens, intraocular lens, dental prosthesis, implantable medical device such as a heart valve or a medical instrument which contacts the body such as an endoscope or catheter.

Brief Description of the Drawings

FIG. 1 shows the high-performance liquid chromatography (HPLC) trace obtained for the synthetic humic acid product obtained from 2,5-dihydroxyphenylacetic acid (homogentisic acid), as described in Examples 10 and 11;

FIG. 2 shows the high-performance liquid chromatography (HPLC) trace obtained for a typical commercially-available natural humic acid;

FIG. 3 shows the p24 expression of HIV-positive cells harvested 6 and 8 days after treatment with synthetic humic acids prepared as described in Examples 10 and 11. Also shown for comparison are the results obtained for natural humic acid that has been dialyzed, and natural humic acid that has been dialyzed and freeze-dried. C+ and C- are positive and negative controls, respectively.

Detailed Description Of The Preferred Embodiment

5 An object of the present invention is to provide new and improved combinations of chemical processes for the preparation of synthetic phenolic polymeric materials, also known as synthetic humic acids, whose physicochemical properties and attributes are reproducible, and which simulate those of typical commercially-available natural humic acids and other soil extracts, which contain no ionic salts or other compounds of molecular weight less than 500 daltons, which have a minimum molecular weight of 500 daltons, and which processes shall be suitable for scaleup directly to industrial levels that provide economically acceptable yields.

10 Still another object of the present invention is to provide human or animal blood product compositions comprising an anti-viral amount of a synthetic humic acid prepared according to the above processes.

15 Still another object of the present invention is to provide methods for reducing or eliminating the amount of virus in human or animal blood products by contacting said blood products with an anti-viral amount of a synthetic humic acid prepared according to the above processes.

Still another object of the present invention is to provide compositions for treating or preventing human or animal viral diseases comprising an anti-viral amount of a synthetic humic acid prepared according to the above processes.

20 Still another object of the present invention is to provide compositions for treating or preventing human or animal microbial diseases comprising an antimicrobial amount of a synthetic humic acid prepared according to the above processes.

According to the present invention the starting compounds used in the chemical processes employed for production of synthetic humic acids are known materials that are readily available commercially.

25 Generally speaking, the chemical processes for the preparation of synthetic humic acids of the invention are characterized by the following steps:

- A. Dissolving the starting organic compound or mixture of organic compounds in an aqueous solution comprising distilled water or sodium hydroxide.
- 30 B. Adjusting the pH of the aqueous solution resulting from step A) to between 8 and 11 if necessary.

- 5
- 10
- 15
- C. Adding an alkaline periodate salt or alkaline-earth periodate salt to the aqueous solution resulting from step B).
 - D. Maintaining the temperature of the solution resulting from step C) between 35 and 80⁰C *for a* period of 30 minutes to 100 hours.
 - E. Adding one or more compounds or salts selected from the group consisting of boric acid, borate salts, alkaline earth salts, transition metal salts, alkaline sulfides, alkaline earth sulfides or transition metal sulfides to the aqueous solution resulting from step D);
 - F. Allowing the aqueous solution resulting from step E) to stand with or 10 without stirring at room temperature between 2 and 48 hours.
 - G. Removing molecules from the solution resulting from step F) below about 500 to about 10,000 daltons.
 - H. Concentrating the solution resulting from step G).
 - I. Removing the water from the solution resulting from step H) —if 15 necessary.

20

25

The starting organic compound in step A) above can be one, or more than one in combination, of different compounds taken from the group consisting of starting organic compounds illustrated in Tables 1 and 2. Starting organic compounds illustrated in Table I are comprised of a single benzene ring with six substituents R1-R6, wherein R1-R6 can be any one of the indicated atom or functional groups, as long as at least one of RI-R6 is a hydroxy (-OH) functional group. Preferably, at least one of R1-R6 is a hydroxy (-OH) functional group and at least one of the remaining substituents R1-R6 contains a carboxylic acid functional group. More preferably, two of R1-R6 are hydroxy (-OH) functional groups and one of the remaining substituents RI-R6 contains a carboxylic acid functional group. Homogentisic acid, which is 2,5-dihydroxyphenylacetic acid, is a particularly preferred starting organic compound.

30

Various initial concentrations of starting organic compounds in distilled water can be employed and no lower or upper limits are uniformly required. A low concentration solution of sodium hydroxide, such as 0.1 Normal, may also be employed as a diluent for the starting organic compound. The appropriate initial concentration of the starting organic compound or compounds is determined by the

TABLE 1, CONT.

-OH(0113)002C113
-CH(CH3)01120H
-011(0113)011200113
-011(0113)01120110
-0H(0113)011200211
-0H(OHa)CH20020113
-OH(OH)2
-011(011)00113
-011(011)0110
-011(011)00211
-011(011)0020113
-011(00113)011
-011(00113)2
-CH(OCHa)C110
-OH(00H3)00211
-011(00113)0020113
-011(011)0112011
-011(011)011200113
-011(011)01120110
-011(011)011200211
-011(011)01120020113
-CH(OCHa)0112011
-011(00113)011200113
-011(00113)01120110
-011(00113)011200211
-011(00113)01120020113
-(0112)3011
-(0112)300113
-(0112)30110
-(0112)300211
-(0112)30020113
-011011011 (cis or trans)
-01101100113 (cis or trans)
-0110110110 (cis or trans)
-01101100211 (cis or trans)
-0110110020113 (cis or trans)
-0112011011011 (cis or trans)
-011201101100113 (cis or trans)
-01120110110110 (cis or trans)
-011201101100211 (cis or trans)
-01120110110020113 (cis or trans)

TABLE 2





TABLE 2, CONT.



Tetrahydroxybenzoquinone

time or following the addition of the periodate in step C). Sulfides contribute to the phenolic polymeric structure, the stability of the structure and its biological activity. Sodium sulfide nonahydrate is a particularly preferred sulfide. The concentration of the sulfide is generally between 1% and 20% of the starting organic compound or compounds on a molar basis. Thus, if 10 millimoles of starting organic compound is employed, 0.1 to 2 millimoles of sulfide may be employed. Preferably, a molar concentration of sulfide which is 5%-15% of the molar concentration of the starting organic compound or compounds is employed. Most preferably, a molar concentration of sulfide which is 8% to 12% of the molar concentration of the starting organic compound or compounds is employed. The exact concentration of sulfide to be used can be determined by conventional synthetic yield optimization techniques.

The pH-adjusted aqueous solution containing the starting organic compound, periodate and optional sulfide is placed in a water-bath or other thermostat heating device at between 35⁰C and 80⁰C for a period of 30 minutes to 100 hours in step D). Alternatively, the aqueous solution itself may be thermostated between 35⁰C and 80⁰C for a period of 30 minutes to 100 hours. A preferred temperature and time is 50⁰C for 30 minutes.

Following this period, salts are added to the solution resulting from step D) alone or in combination in step E). Salts containing boron, calcium and other alkaline earths, iron and other transition metals are preferred. Such salts additionally contribute to the phenolic polymeric structure, its stability and biological activity. Boric acid or boron-containing-borate salts such as sodium borate are particularly preferred, as are alkaline earth salts, such as calcium sulfate dihydrate and transition metal salts, such as ferrous sulfate heptahydrate. The concentrations of each of the salts employed is generally between 0.1% and 20% of the starting organic compound or compounds on a molar basis. Preferably, a molar concentration of salt which is 0.2% to 10% of the molar concentration of the starting organic compound or compounds is employed. Most preferably, a molar concentration of salt which is 0.2% to 2% of the molar concentration of the starting organic compound or compounds, is employed. The exact concentration to be used can be determined by conventional synthetic yield optimization techniques.

The solution resulting from step E) is allowed to stand at room temperature with or without stirring for a period of time from 2 to 48 hours in step F). Any precipitate formed at this stage is removed via conventional centrifugation.

5 Molecules are removed from the solution resulting from step F) below about 500 to about 10,000 daltons in step G). A variety of known conventional techniques can be employed such as preparative chromatography, ultrafiltration or dialysis. Molecules are preferably removed from the solution resulting from step F) by employing dialysis in step G) with a flow-through open-channel or screen membrane apparatus consisting of a sandwich-type membrane of lower molecular-weight cutoff of 500-10,000 daltons
10 until the conductivity of the solution has dropped to 200 microsiemens or less. Most preferably, molecules are removed from the solution resulting from step F) by employing dialysis in step G) until the conductivity of the solution has dropped to 30 microsiemens or less. A Pall Filtron Ultrasette® Tangential Flow Device or Mini-Ultrasette® Tangential Flow Device used with a Pall Filtron Ultralab® Specialized
15 Pump and Reservoir System are preferred for solution dialysis.

The conductivity of the solution processed in step G) above can conveniently be monitored with a flow-through conductivity cell and conductivity meter. Alternatively, a simple inexpensive hand-held combination conductivity cell-conductivity meter (e.g., a Nalcometer Model MLN) can be employed. Before
20 removing the water from the solution in step H) above, the solution resulting from step G) above can be further dialyzed with a flow-through apparatus consisting of a sandwich-type membrane of molecular weight cutoff of 50,000 daltons. In this case the filtrate solution, not the retentate, is saved for further concentrating and processing according to steps H) and I). The resultant product will have a molecular-
25 weight range of 500-50,000 daltons.

If the solution resulting from either steps G) or H) above is to be stored as an aqueous solution for long periods of time for later application or use, for example as an anti-viral treatment solution, anti-viral therapy, anti-microbial therapy, a spray-on fertilizer or soil amendment, it can be filtered through standard 0.2 to 0.4 micron
30 filters to remove bacteria and viruses, that is, can be made sterile by filtration.

Alternatively, the aqueous solution from either steps G) or H) can be autoclaved for 5-60 minutes at 100~150°C to produce a sterile solution.

5 A final optional step I) in the process of the present invention involves removing water from the solution resulting from step H). When freeze-drying is employed as the method of water removal in step I) above, the resultant product is a light fluffy dark-colored powder that is subject to static electricity effects. To minimize these effects, a small amount of mannose or other sugar can be added to the solution resulting from step H) just prior to freeze-drying. Water removal from the product can be carried out by means other than freeze-drying in step I) above, such as by heat
10 evaporation with or without vacuum, by rotary evaporation, by spray-drying, or by any other solvent-removal technique that is convenient as well as economical for aqueous solutions. The dried powder obtained from step I) above can be autoclaved for 15-30 minutes at 100~120°C to produce a sterile powder.

The synthetic humic acid materials produced according to the chemical
15 processes and separation and isolation procedures of the present invention exhibit the physicochemical properties and attributes of typical naturally-occurring commercially-available humic acids and other soil extracts.

A facile method of examining the physicochemical characteristics of the product yielded by steps A) through H) above, or by modifications thereto, is high
20 performance liquid chromatography (HPLC). The chromatographic fingerprint pattern so obtained from HPLC also offers a convenient means of comparing one product with another, as well as comparing each of the synthetic products with naturally-occurring humic acids and other soil-extract materials. The HPLC method is thus used to determine the reproducibility of the physiochemical properties and attributes of the
25 synthetic phenolic polymeric materials, as well as to determine if the aforementioned properties and attributes simulate the physiochemical properties and attributes of typical commercial-available natural humic acids and other soil extracts. The latter determination of simulation is done in the conventional manner employing HPLC; e.g., by visually and quantitatively comparing the HPLC chromatographic fingerprint
30 patterns of the materials. The fingerprint patterns of the two materials, one synthetic and one natural, need not be 100% identical to conclude that the

physiochemical properties and attributes of the synthetic phenolic polymeric material simulates the physiochemical properties and attributes of the natural humic acid. An approximate correspondence between the aforementioned HPLC fingerprint patterns is all that is required to conclude that the synthetic material simulates the natural material.

5 In general, even a 75% visual correspondence in 2 HPLC fingerprint patterns is all that is necessary to conclude that one material simulates another. A useful fingerprint pattern for natural as well as synthetic soil extract materials can be obtained as follows. The column is comprised of a packing, typically reversed-phase polymer PRP- I (Hamilton Co.), of particle size 5 microns, and being 150 millimeters in length by 4.1

10 millimeters inside diameter. The mobile phase is comprised of three solutions. Solution A is 0.1 Normal aqueous sodium hydroxide. Solution B is 0.05 Normal of so-called Prideaux universal buffer, which is made by combining 4.25 grams of sodium nitrate (NaNO_3), 12.37 grams of boric acid (H_3BO_3), 23.06 grams of phosphoric acid (H_3PO_4), and 12.01 grams of acetic acid ($\text{CH}_3\text{CO}_2\text{H}$) with 4 liters of distilled water. Solution C is

15 100% methanol (CH_3OH). The mobile-phase gradient employed for an HPLC run consists of 40% solution A plus 60% solution B at the beginning, which composition is changed in a linear manner to 100% solution A after 20 minutes. The mobile phase is then changed linearly again to 10% A plus 90% C over the next 5 minutes, which final composition is held for the purpose of a column wash for the next 35 minutes. The

20 mobile-phase flow rate is 1 milliliter per minute. The detector is UV-Visible, which is set at 340 nanometers. The chart speed is typically 0.5 centimeter per minute. The sample loop size is 5-20 microliters. Solutions are prepared for analysis by dissolving 1-10 grams of dried sample in 100 milliliters of 0.1 normal aqueous sodium hydroxide of pH 8-10. The chemical processes and separation and isolation procedures of the

25 present invention are suitable for scaleup directly to industrial levels that provide economically acceptable yields.

The chemical processes and separation and isolation procedures of the present invention can produce synthetic product yields approaching 100%. More typically, approximately 0.08 to 0.65 g of synthetic humic acid can be produced

30 from 10 millimoles of starting organic compound or compounds in 300 ml. These procedures can be scaled up to pharmaceutical production scales employing 10,000

to 20,000 liters or more of initial solution containing the starting organic compound or compounds. A total yield of between approximately 2.7 and 21.7 kg of synthetic humic acid can be achieved utilizing a 10,000 liter thermally jacketed stainless steel tank and a concentration of starting organic compound of 10 millimoles per 300 ml.

5 A single anti-viral treatment may employ milligram amounts of synthetic humic acid. 20 kg of synthetic humic acid represents 2 million units of anti-viral product at 10 mg per unit. Even at a treatment cost of \$ 0.10 per unit, this represents \$ 200,000 of synthetic humic acid. Since the starting organic compounds utilized in the present invention are relatively inexpensive, the synthesis yields of the chemical processes and separation and isolation procedures of the present invention are economically very acceptable.

10

Examples 1 through 9 are illustrative of the variety of starting organic compounds that can be employed in the process of the present invention. It was not considered necessary to carry out all steps of the process of the present invention to illustrate starting compound variety. More particularly, Examples 1 through 9 are illustrative of all steps of the process of the invention with the exception of step E).

15

EXAMPLE 1

Preparation of a synthetic humic acid from 2,S-dihydroxybenzoic acid (gentisic acid). The starting organic compound is shown in Table 1, and consists of R₁ CO₂H, R₂,R₅ = -OH, and R₃,R₄,R₆ -H. 1.55 grams (10 millimoles) of gentisic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The solution pH is adjusted to 8.5 with 6 Normal HCl 0.54 gram of sodium periodate (NaIO₄ 2.5 millimoles) is added, and the solution is placed in a water-bath at 50~ C for 30 minutes. The solution is allowed to stand at room temperature overnight. Any precipitate is removed by centrifugation. The solution is dialyzed with a 3,000-dalton cut-off flow-through open-channel or screen membrane system (Pall Filtron: Ultrasette®7 Tangential Flow Device or Mini-Ultrasette® 7 Tangential Flow Device used with a Pall Filtron Ultralab® 7 Specialized Pump and Reservoir System) to a conductivity of 30 microsiemens or less against distilled water. The dialysis apparatus is then used to concentrate the solution to about 200 milliliters. The solution can be saved at this point for further use as an aqueous solution; or it can be freeze-dried to

20

25

30

a powder. (0.05-0.2 gram of mannose or other suitable carbohydrate can be added to the solution prior to freeze-drying to reduce static electricity effects associated with the freeze-dried powder.) The yield of synthetic soil extract is 0.2 gram.

The following examples 2-9 employ the synthesis procedure of Example I 5 beginning with the adjustment of solution pH.

EXAMPLE 2

Preparation of a synthetic humic acid from 3, 4-dihydroxyphenylacetic acid (homoprotocatechuic acid). The starting organic compound, 3,4-dihydroxyphenylacetic acid, is shown in Table 1, and consists of $R_1 = -CH_2CO_2H$, $R_3, R_4 = -OH$, and $R_2, R_5, R_6 = -H$. 1.68 grams (10 millimoles) of homoprotocatechuic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.24 gram.

EXAMPLE 3

Preparation of a synthetic humic acid from dl-(3,4-dihydroxyphenyl)hydroxyacetic acid (dl-3, 4-dihydroxymandelic acid). The starting organic compound, dl-(3,4-dihydroxyphenyl)hydroxyacetic acid is shown in Table 1, and consists of $R_1 = -CH(OH)CO_2H$, $R_3, R_4 = -OH$, and $R_2, R_5, R_6 = -H$. 1.84 grains (10 millimoles) of dl-3,4-dihydroxyinandelic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.08 gram.

EXAMPLE 4

Preparation of a synthetic humic acid from aurintricarboxylic acid The chemical structure of the starting organic compound is shown in Table 2. 4.2 grams (10 millimoles) of aurintricarboxylic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 4.7 grams.

EXAMPLE 5

Preparation of a synthetic humic acid from 3-(3, 4-dihydroxyphenyl)propenoic acid (caffeic acid). The starting organic compound is shown in Table 1, and consists of $R_1 = -CHCHCO_2H$, $R_3, R_4 = -OH$, and $R_2, R_5, R_6 = -H$. 1.80 grams (10 millimoles)

of caffeic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.65 gram.

EXAMPLE 6

5 *Preparation of a synthetic humic acid from tetrahydroxybenzoquinone.* The chemical structure of the starting organic compound is shown in Table 2. 1.72 grams (10 millimoles) of tetrahydroxybenzoquinone is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.016 gram.

EXAMPLE 7

10 *Preparation of a synthetic humic acid from 1, 4-dihydroxybenzene (hydroquinone).* The starting organic compound is shown in Table 1, and consists of R_1, R_4 -OH, and $R_2, R_3, R_5, R_6 = -H$. 1.10 grams (10 millimoles) of hydroquinone is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.16 gram.

EXAMPLE 8

15 *Preparation of a synthetic humic acid from 3,4,S-trihydroxybenzoic acid (gallic acid).* The starting organic compound is shown in Table 1, and consists of $R_1 = -CH_2CO_2H$, R_3, R_4, R_5 -OH, and $R_2, R_6 = -H$. 1.70 grams (10 millimoles) of gallic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.10 gram.

EXAMPLE 9

20 *Preparation of a synthetic humic acid from 2,S-dihydroxyphenylacetic acid (homogentisic acid).* The starting organic compound is shown in Table 1, and consists of $R_1 = -CH_2CO_2H$, R_2, R_5 -OH, and $R_3, R_4, R_6 = -H$. 1.68 grams (10 millimoles) of homogentisic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The remaining procedure follows that of Example 1. The yield of synthetic soil extract is 0.20 gram.

30

The following Examples 10-13 are illustrative of the entire process of the present invention including step E). Examples 10-13 illustrate that the synthetic humic acid materials produced according to the chemical processes and separation and isolation procedures of the present invention exhibit the physicochemical properties and attributes of typical naturally-occurring commercially-available humic acids and other soil extracts. Examples 10-13 also illustrate that the therapeutic indications of the synthetic humic acids produced according to the chemical processes and separation and isolation procedures of the present invention are those of soil extracts and humic acids in general, that is to say for viral-related and other disorders and diseases of inflammatory, microbial and other origin.

EXAMPLE 10

Preparation of another synthetic humic acid from 2, 5-dihydroxyphenylacetic acid (homogentisic acid). The starting organic compound is shown in Table 1, and consists of $R_1 = -CH_2CO_2H$, $R_2, R_5 = -OH$, and $R_3, R_4, R_6 = -H$. 1.0 gram (6 millimoles) of homogentisic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The solution pH is adjusted to 8.5 with 6 Normal HCl. 0.32 gram of sodium periodate ($NaIO_4$ 1.5 millimole) and 0.12 gram of sodium sulfide nonahydrate ($Na_2S \cdot 9H_2O$; 0.5 millimole) are added, and the solution is placed in a water-bath at $50^{\circ}C$ overnight. 0.001 gram of boric acid ($H_3B_3O_3$ 0.016 millimole), 0.021 gram of ferrous sulfate heptahydrate ($FeSO_4 \cdot 7H_2O$; 0.075 millimole), and 0.006 gram of calcium sulfate dihydrate ($CaSO_4 \cdot 2H_2O$; 0.035 millimole) are added and the solution is stirred for 2 hours at room temperature. Any precipitate is removed by centrifugation. The solution is dialyzed with a 3,000-dalton cut-off flow-through open-channel or screen membrane system (Pall Filtron: Ultrasette® 7 Tangential Flow Device or Mini-Ultrasette® 7 Tangential Flow Device used with a Pall Filtron Ultralab 7 Specialized Pump and Reservoir System) to a conductivity of 30 microsiemens or less against distilled water. The dialysis apparatus is then used to concentrate the solution to about 200 milliliters. The solution can be saved at this point for further use as an aqueous solution; or it can be freeze-dried to a powder. (0.05-0.2 gram of mannose or other suitable carbohydrate can be added to the solution prior to freeze-drying to reduce static electricity effects associated with the freeze-

dried powder.) The yield of synthetic soil extract is 0.23 gram. The HPLC trace of the synthetic soil extract obtained in this Example is illustrated in Figure 1. Peaks 1-6 are produced by this example. Peak 5 is under the shoulder of Peak 4 and not overtly apparent. A mathematical first derivative of the detector signal versus time can more clearly show Peak 5. Figure 2 shows the HPLC trace of a typical commercially-available natural humic acid. Peak 6 in Figures 1 and 2 is produced by a column wash with 90-100% v/v methanol and also contains synthetic humic acid. It can be seen that with the exception of the relative amounts of material in Peaks 2,4 and 6, the remainder of the HPLC traces in Figures 1 and 2 are essentially equivalent. Thus, the synthetic procedure of the present invention produced a humic acid material with physicochemical characteristics that are essentially equivalent to those of a commercially-available soil extract.

EXAMPLE 11

Preparation of still another synthetic humic acid from 2, S15 dihydroxyphenylacetic acid (homogentisic acid). The starting organic compound is shown in Table 1, and consists of $R_1 = -CH_2CO_2H$, $R_2, R_5 = -OH$, and $R_3, R_4, R_6 = -H$. 1.68 gram (10 millimoles) of homogentisic acid is dissolved in 300 milliliters of 0.1 Normal aqueous sodium hydroxide (NaOH). The solution pH is adjusted to 8.5 with 6 Normal HCl. 0.75 gram of sodium periodate ($NaIO_4$ 3.5 millimoles) and 0.24 gram of sodium sulfide nonahydrate ($Na_2S \cdot 9H_2O$; 1 millimole) are added, and the solution is placed in a water-bath at $50^{\circ}C$ overnight. 0.006 gram of boric acid (H_3BO_3 0.1 millimole), 0.28 gram of ferrous sulfate heptahydrate ($FeSO_4 \cdot 7H_2O$; 1 millimole), and 0.017 gram of calcium sulfate dihydrate ($CaSO_4 \cdot 2H_2O$; 0.1 millimole) are added and the solution is stirred for 48 hours at room temperature. Any precipitate is removed by centrifugation. The solution is dialyzed with a 3,000-dalton cut-off flow-through open-channel or screen membrane system (Pall Filtron: Ultrasettetm 7 Tangential Flow Device or Mini-Ultrasettetm 7 Tangential Flow Device used with a Pall Filtron UltralabTM 7 Specialized Pump and Reservoir System). The dialysis apparatus is then used to concentrate the solution to about 200 milliliters. The solution can be saved at this point for further use as an aqueous solution; or it can be freeze-dried to a powder. (0.05-0.2 gram of mannose or other suitable carbohydrate can be added to

the solution prior to freeze-drying to reduce static electricity effects associated with the freeze-dried powder.) The yield of synthetic soil extract is 0.47 gram. The HPLC trace of the synthetic soil extract obtained in this Example is identical to that described in Example 10 and illustrated in Figure 1.

5 **EXAMPLE 12**

Anti-viral properties of synthetic humic acid prepared according to Examples 10 and 11. Several hundred milligrams of synthetic humic acid are prepared according to the procedures of Examples 10 and 11. The antiviral properties of these materials was assessed according to the following methods:

10 Jurkat cells obtained from the American Type Culture Collection (Rockville, Maryland) are subcultured every fifth day using RPMI-1640 medium supplemented with 2 millimolar L-glutamine and 15 percent by volume fetal bovine serum (FBS). Cell counts are determined with a Coulter particle counter (Coulter Corporation, Hialeah, Florida). The cells are infected with an HIV-1 plasmid construct, pNL4-3 (A. Adachi, H. E. Gendleman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin, .1 *Virology*. 1986, 99, 284-291; cell cultures thereby treated produce high levels of HIV- 1, approximately 1×10^6 particles per milliliter, as measured by electron microscopy). The infected cells are then cultured in complete medium comprised of RPMI-1640 supplemented with 2 millimolar L-glutamine, 15 percent by volume fetal calf serum, and 1 percent by volume Pen-Strep (100 Units of Penicillin and 100 milligrams of Streptomycin per milliliter). The cells are monitored for approximately 20 four weeks prior to use in order to ensure stable HIV-1 production.

Prior to testing the anti-viral efficacy of the synthetic humic acid, Jurkat cell culture supernatants are first tested for HIV-1 p24 production to establish a pretreatment baseline. After confirming the level of virus production, the growth 25 medium is changed and the cell number is adjusted to 1.5×10^6 cells per milliliter. Then, two days prior to administering the synthetic humic acid to be tested, equal volumes of transfected cells are admixed with normal, untreated cells to bring the level of virus production to within the range of the HIV-1 p24 immunoassay. After 24 30 hours, a known quantity of synthetic humic acid is added to the cell blend. The determination of HIV-1 p24 expression after a given number of days following

synthetic humic acid administration is carried out with a solid-phase assay designed for HIV- 1 antigens (HI VAG- 1; Abbott Laboratories, Diagnostic Division, Abbott Park, Illinois; Abbott Quantum II ELISA reader and data reduction module 1.21).

FIG. 3 shows the effect of the synthetic humic acid prepared as described in 5 Examples 10 and 11 on the p24 expression of HI V-positive cells as measured according to the procedures of Example 12. Example 1 la in Figure 3 was prepared exactly according to the procedure of Example II. Example 11 b in Figure 3 was prepared according to the procedure of Example 11 with the additional step of freeze-drying the final solution. Shown for comparison are the results obtained with natural 10 humic acid that was subjected to dialysis as described in Examples 1-11; and natural humic acid that was subjected to dialysis with subsequent freeze-drying as described in Examples 1-11. The results show significant reductions in p24 expression for all samples. Additionally, at day 12, no p24 was detected within the experimental error of the method (none greater than the C- control).

15 **EXAMPLE 13**

Toxicity of synthetic humic acid prepared according to Example 10. Several hundred milligrams of synthetic humic acid are prepared according to the procedure of Example 10.

Five units of 450 milliliters each of whole human blood are collected into 20 CP2D/AS-3 Leukotrap RC-PL systems. The blood is rested for 3 hours at room temperature. Each sample is weighed, and then centrifuged at 2820 revolutions per minute (2312 gravities) for 3 minutes, 44 seconds. The blood samples are then expressed through ATS-LPL filters into platelet storage bags. The filtration time is noted. The LR-PRP is centrifuged at 3600 revolutions per minute (3768 gravities) for 25 7 minutes. All but about 55 grams of platelet poor plasma is removed from each sample. The platelet concentrates are rested for 90 minutes at room temperature, and are then weighed and placed in a platelet incubator. RCM1 filters are primed with AS-3 solution. The primary bags are hung at a height of 60 inches above empty AS-3 bags, such that filtration occurs by gravity. The filtration time is noted, and the LR30 30 RCC systems are sealed off 3 inches below the RCM1 filters. Each RCM1 filter together with 6 inches of tubing and the LR-RCC, including the donor identification

5 tube segment, are weighed. Samples are taken at this point for post-filtration testing (LR-RCC). At day 1 sufficient synthetic humic acid is added to each platelet concentrate so as to make its concentration 25 micrograms per milliliter. Treated platelet concentrates are then incubated in a platelet incubator for 1 hour, following which samples of each platelet concentrate are taken for testing. Subsequent samples are also taken on day 5 for further testing.

10 Table 3 shows the effect of the synthetic humic acid prepared as described in Example 10 on the viability of platelet concentrates as measured according to the procedures of this Example. The results are all nominal, that is, the synthetic humic acid has no effect on platelet viability (i.e., is nontoxic). These results are particularly noteworthy, as blood platelets are known to be sensitive to a variety of chemical agents. It is for this reason that few safe anti-viral treatments are available for blood platelets.

15 Examples 12 and 13 illustrate that synthetic humic acids prepared according to the above processes and separation and isolation procedures of the present invention can be combined in anti-viral amounts with blood products to form blood product compositions. Synthetic humic acids may be added in anti-viral amounts to human or animal blood products such as whole blood, blood plasma, blood platelets or other blood products containing blood fractions such as haemophilia factor VIII, haemophilia factors IX and V, albumin, IgG, IgM or other blood proteins or blood materials to reduce or eliminate viral activity. Synthetic humic acids may be added in anti-viral amounts to both liquid and solid blood products. Synthetic humic acid will have application to blood materials including all blood materials where the solvent/detergent (SD) treatment applies. In direct contrast to the SD treatment, which is ineffective for nonenveloped viruses, synthetic humic acid prepared according to the present invention has anti-viral activity against both lipid enveloped and nonenveloped viruses and thus has broader application. An anti-viral amount of synthetic humic acid is an amount that is known from the prior art regarding anti-viral amounts of humic acids to be useful in reducing or eliminating viral activity. Generally, an anti-viral amount useful in blood product compositions for reducing or eliminating viral activity in liquid blood product compositions is a concentration of synthetic humic acid

20
25
30

TABLE 3

between 5 and 1000 micrograms per milliliter of liquid blood product composition. This same concentration range applies to solid blood product compositions containing dried synthetic humic acid upon dissolution in solution prior to use. The exact amount to be utilized to reduce or eliminate viral activity depends upon the particular virus and blood product and can be determined with conventional anti-viral test procedures known in the art. Whole blood, blood plasma or other blood products suspected to be contaminated or contaminated with HIV or hepatitis virus can be modified, for example, with the addition of about 10 to about 200 micrograms per milliliter of synthetic humic acid. Examples 14 and 15 are illustrative of blood product compositions containing anti-viral amounts of synthetic humic acid prepared according to the processes and separation and isolation procedures of the present invention.

Example 14

Whole human blood composition containing 25 ug/milliliter of a synthetic humic acid from 2,5-dihydroxyphenylacetic acid (homogentisic acid). The blood product composition follows:

Whole human blood: 1 liter

Synthetic humic acid: 25 mg

Example 15

Human haemophilia factor VIII composition containing a synthetic humic acid from 2,5-dihydroxyphenylacetic acid (homogentisic acid). The blood product composition follows:

Human haemophilia factor VIII: 1-5ml vial*

Synthetic humic acid: 125 ug

*Note: This is a vial containing sterile highly purified lyophilized factor VIII concentrate intended for dilution with 5ml of sterile injectable saline and containing 3900 units (IU) of factor VIII at a concentration of 100 IU/mg of protein.

Synthetic humic acids prepared according to the above processes and separation and isolation procedures of the present invention can be utilized in anti-viral amounts as defined above in methods for reducing or eliminating the amount of virus in human or animal blood products. Generally, such methods involve contacting the blood product in some way with an anti-viral amount of synthetic humic acid. Various

means of contacting can be employed, such as direct injection of a sterile solution containing said anti-viral amount into said blood product. A particularly preferred method involves the usage of so-called "dual bag" technology for intravenous solutions. This method employs a plastic bag with two separate chambers and a
5 connecting path between them. The two chambers may vary in volume and the volume ratio between them. The two chambers may contain two different drugs or for the purpose of employing the present invention, a blood product in one chamber and the synthetic humic acid in the other chamber. The connecting path is closed until the product is ready to be used. The path can be opened with a valve arrangement or by
10 breaking a seal between the two chambers. The seal is typically broken without compromising the sterility of the products in both chambers. Dual bag sterile solution technology is available from Abbott Laboratories in Illinois, McGaw in California and other companies. Alternatively, a blood product may be contacted with an anti-viral amount of synthetic humic acid during the processing of the blood product prior to or
15 including the final processing step wherein the blood product is placed into its final container for patient use. Due to the nontoxic nature of synthetic humic acid as prepared herein, it is not necessary to separate the humic acid from the blood product prior to use of the blood product. It has already been disclosed herein that it is necessary to separate the detergents in the solvent/detergent (SD) blood treatment
20 method from the blood product utilizing extraction with soybean or castor oil and chromatography on insolubilized C18 resin. Methods for reducing or eliminating the amount of virus in human blood products employing synthetic humic acid have an additional advantage over the SD methods in that unlike the SD methods, both lipid enveloped and nonenveloped viruses can be inactivated. Additionally, unlike various
25 heat treatments or ultraviolet light irradiation of blood products, essentially no loss of blood product is observed with synthetic humic acid treatment methods. Methods for reducing or eliminating the amount of virus in blood products employing synthetic humic acid can be combined with the solvent/detergent (SD) blood treatment method or other blood treatment methods, including heat treatments, ultraviolet irradiation or
30 other methods. One or more of the aforementioned blood treatment methods may be combined with the humic acid treatment method.

Example 16 illustrates that synthetic humic acids prepared according to the above processes and separation and isolation procedures of the present invention can be utilized in anti-viral amounts in methods for reducing the amount of virus in human blood products.

5 **Example 16**

Method for the reduction of the amount of virus in human blood bags with the use of synthetic humic acid from 2,5-dihydroxyphenylacetic acid (homogentisic acid).

The antiviral properties of the synthetic humic acid material prepared according to the procedure of Example 10 are assessed according to the following methods: In this
10 example, Bovine Viral Diarrhea Virus (BVDV) is utilized as an indicator virus for anti-viral activity. BVDV is a lipid-enveloped virus and is known to be a good indicator virus for anti-viral activity, including anti-human immunodeficiency virus activity. A titered virus stock of BVDV at a TCID₅₀ of 1 OE-7 is prepared. Twelve blood bags containing blood platelets are obtained (one for each humic acid concentration, 0,10,50
15 and 100 ug/ml, performed in triplicate). The method for the reduction of the amount of virus in human blood bags with the use of synthetic humic acid involves a simple addition of a sterile volumetric amount of synthetic humic acid in aqueous solution to each blood bag. Specifically, a sterile liquid aliquot of a 100 ug/ml concentration of synthetic humic acid in distilled water is added to each blood bag containing between
20 40 and 60 ml of blood product such that the final concentration of humic acid was 10, 50 or 100 ug/ml. Bags are sampled at the following intervals: T₀ hours as a pre-inoculation control; T₁ hour post inoculation with the virus stock (at T₁ hour post inoculation the humic acid is added); at T₂ hours post inoculation another sample is pulled. Additional samples are pulled at T₂₄ hours, T₇₂ hours and T₁₂₀ hours.
25 Quantitative virus cultures are prepared from the pulled samples and the resulting TCID₅₀s and log reductions are determined for each humic acid concentration. The results of the testing show that synthetic humic acid prepared according to the present invention can successfully be used in methods for reducing the amount of virus in human blood products.

30 Synthetic humic acid prepared according to the above processes and separation and isolation procedures of the present invention can be utilized in anti-viral amounts

in compositions for treating or preventing human or animal viral diseases. Synthetic humic acid containing compositions are suitable for treating or preventing human or animal viral diseases for which natural humic acid materials have been shown to be useful. Thus, synthetic humic acid compositions are suitable for treating or preventing human disease caused by Human Immunodeficiency Virus (HIV), Herpes Simplex Virus and other human viruses. Synthetic humic acid compositions are also suitable for treating or preventing diseases caused by the entire picornavirus family including the current five known genera of viruses: (1) aphthoviruses, (2) cardioviruses, (3) hepatoviruses (previously classified as enteroviruses), (4) reteroviruses (which mainly constitute a combination of the previous genera rhinovirus and enterovirus), and (5) a new genus, with a single representative to date, the echovirus 22. Compositions suitable for various routes of administration and particular viral diseases can be prepared. An anti-viral amount of synthetic humic acid for a particular viral disease can be determined from the known anti-viral amount of natural humic acid known to be useful for the same particular viral disease. A variety of compositions comprising an anti-viral amount of synthetic humic acid and at least one physiologically acceptable excipient can be prepared. Compositions comprising physiologically acceptable excipients suitable for intravenous injection, intramuscular injection, topical application, oral ingestion, nasal spray administration, metered-dose inhalation administration and vaginal and anal suppository administration can be prepared with known excipients and methods. Examples 17-21 are illustrative of the foregoing compositions.

Example 17

Injectible solution composition for treating human immunodeficiency virus (HIV) infection containing an anti-viral amount of synthetic humic acid from 2,5-dihydroxyphenylacetic acid (homogentisic acid) and injectible solution excipients:

Sodium chloride	9.00 gram
Synthetic humic acid	500 mg
Distilled water	q.s. to 1 liter

The pH of the above solution can additionally be adjusted to 7.4 with 1 Normal sodium hydroxide prior to adding all of the water. This injectable solution composition can be prepared by conventional methods for preparing injectable sterile solutions.

Example 18

5 *Topical ointment composition for treating human herpes simplex virus (HSV-I or HSV-II) infection containing an anti-viral amount of synthetic humic acid from 2, 5-dihydroxyphenylacetic acid (homogentisic acid) and topical formulation excipients:*

	Synthetic humic acid	3.0	gram
10	Cetostearyl alcohol	27	gram
	Liquid paraffin	20	gram
	White soft paraffin	50	gram

Example 19

15 *Topical cream composition for treating human herpes simplex virus (HSV-I or HSV-II) infection containing an anti-viral amount of synthetic humic acid from 2, 5-dihydroxyphenylacetic acid (homogentisic acid) and topical formulation excipients:*

	Synthetic humic acid	2.4	gram
	Cetosteryl alcohol	5	gram
20	Liquid paraffin	50	gram
	Distilled water	add to 100	gram

Example 20

25 *Topical solution composition for treating human herpes simplex virus (HSV-I or HSV-II) infection containing an anti-viral amount of synthetic humic acid from 2, 5-dihydroxyphenylacetic acid (homogentisic acid) and topical formulation excipients:*

	Synthetic humic acid	2.4	gram
	Sodium sulfide	1.0	gram
	Colloidal sulfur	1.4	gram
30	Sodium chloride	2.2	gram
	Potassium sorbate	0.2	gram

Distilled water q.s. to 100 ml

Note that the above composition contains the same amount of humic acid disclosed by Wagner in German patent DE 3830333.

Example 21

5 *Ingestible lozenge composition for treating human immunodeficiency virus (HIV) infection containing an anti-viral amount of synthetic humic acid from 2,5-dihydroxyphenylacetic acid (homogentisic acid) and ingestible lozenge excipients.*

	Synthetic humic acid	500 mg
	Menthol	3.6 mg
10	Cetylpyridinium chloride	1.4 mg
	Cherry flavor	100 mg
	Glucose	500 mg
	Sucrose	500 mg

15 Other excipients may also be added to the above composition. Colorants such as D&C Red No. 33, FD&C Red No. 40 or other colorants may be used. Other flavoring agents may also be utilized in lozenge formulations as well preservatives other than cetylpyridinium chloride. The aforementioned excipients as well as other excipients not mentioned are all known in the art and can be employed in amounts previously used in lozenge formulas. The composition of Example 21 is also useful

20 for treating the common cold, which is caused by members of the rhinovirus family. Nasal spray compositions containing synthetic humic acid are also particularly useful for treating the common cold.

25 Compositions comprising physiologically acceptable excipients suitable for disinfection and preservation of medical devices can be prepared with known excipients and methods. A variety of medical devices which contact the body can be disinfected or preserved with compositions containing synthetic humic acid. These medical devices can be disinfected or preserved before or after bodily contact to prevent viral infection. Contact lenses, intraocular lenses, dental prostheses, implantable medical devices such as heart valves and medical instruments which

30 contact the body such as endoscopes and catheters can be disinfected or preserved with compositions containing synthetic humic acid.

Synthetic humic acid prepared according to the above processes and separation and isolation procedures of the present invention can be utilized in anti-microbial amounts in compositions for treating or preventing human or animal microbial diseases. An anti-microbial amount of synthetic humic acid is an amount that is known from the prior art referenced herein regarding anti-microbial amounts of humic acids to be useful in reducing or eliminating microbial activity. Generally, an anti-microbial amount useful in product compositions for reducing or eliminating microbial activity in liquid product compositions is a concentration of synthetic humic acid between 50 and 2000 micrograms per milliliter of liquid product composition. This same concentration range applies to solid product compositions containing dried synthetic humic acid upon dissolution in solution prior to use. Cronje et al., U.S. 4,999,202, discloses bacteriocidal or bacteriostatic compositions comprising humic acid with higher concentrations. The concentrations employed by Cronje et al. can also be employed herein. The exact amount to be utilized to reduce or eliminate microbial activity depends upon the particular microorganism and product and can be determined with conventional anti-microbial test procedures known in the art. The synthetic humic acids of the present invention have anti-microbial activity comparable to the activity of natural humic acids and other synthetic humic acids referenced herein. Thus, the synthetic humic acids of the present invention will have activity against *cryptosporidium species*, *C. albicans*, *Ent. cloacae*, *Prot. vulgaris*, *l's. aeruginosa*, *S. typhimurium*, *St. aureus*, *St. epidermidis*, *Str. pyrogenes*, *Str. mutans*, *E. ccli* and other organisms. A variety of compositions comprising an anti-microbial amount of synthetic humic acid and at least one physiologically acceptable excipient can be prepared. Compositions comprising physiologically acceptable excipients suitable for intravenous injection, intramuscular injection, topical application, oral ingestion, nasal spray administration, metered-dose inhalation administration and vaginal and anal suppository administration can be prepared with known excipients and methods. The topical compositions of Examples 18-20 also have anti-microbial activity and are illustrative of anti-microbial compositions. Compositions comprising physiologically acceptable excipients suitable for disinfection and preservation of medical devices such as contact lenses can be prepared with known excipients and methods. A variety of

5 medical devices which contact the body can be disinfected or preserved with compositions containing synthetic humic acid. These medical devices can be disinfected or preserved before or after bodily contact to prevent microbial infection. Contact lenses, intraocular lenses, dental prostheses, implantable medical devices such as heart valves and medical instruments which contact the body such as endoscopes and catheters can be disinfected or preserved with compositions containing synthetic humic acid. Example 22 which follows is illustrative of a composition suitable for disinfection and preservation of contact lenses. Example 22 is illustrative of a one bottle contact lens multipurpose disinfecting, preservation (storage), cleaning, rinsing and rewetting solution. This solution provides the necessary antibacterial disinfection activity required by U.S. FDA disinfection efficacy guidelines for contact lens solutions. This solution is nontoxic and extremely comfortable for the eye and thus can be placed directly in the contact lens user's eye without further rinsing with a separate saline solution. The solution can be used with all contact lenses such as conventional hard, soft, rigid, gas permeable and silicone lenses but is preferably employed with soft lenses such as those commonly referred to as hydrogel lenses prepared from monomers such as hydroxyethylmethacrylate, vinylpyrrolidone, glycerolmethacrylate, methacrylic acid or acid esters and the like. Proteolytic enzymes used for cleaning contact lenses, such as those disclosed in U.S. Patent No. 5,356,555 can also be combined with contact lens multipurpose solutions containing synthetic humic acid prepared according to the methods of the present invention. The methods of combining proteolytic enzymes with synthetic humic acid containing multipurpose solutions and the amounts of enzyme and excipients to be employed are the same as disclosed in U.S. Patent No. 5,356,555 which is incorporated herein by reference. Generally, for the purposes of the present invention an aqueous solution containing from 0.0010 w/v³/o to less than or equal to 0.0100 w/v% of the synthetic humic acid disinfecting agent may be used as a contact lens multipurpose solution. Contact lens multipurpose solutions containing synthetic humic acid prepared according to the methods of the present invention have advantages over the prior art contact lens multipurpose solutions containing other disinfecting agents. Synthetic humic acid containing multipurpose solutions achieve equal or greater disinfection efficacy while

providing greater comfort for the contact lens wearer. This is a result of the inherently lower cytotoxicity or toxicity of synthetic humic acid disinfecting agents as compared to prior art disinfecting agents which are presently in use for contact lens multipurpose solutions. The advantages of synthetic humic acid for contact lens applications are also a result of their anionic and neutral polymeric nature. Current contact lens multipurpose solutions contain cationic polymeric disinfecting agents such as polyhexamethylenebiguanide (PHMB) and polyquaternium 1 which have a much higher affinity for the inherently neutral to anionic contact lens polymers. However, the synthetic humic acid prepared according to the present invention is a colored material. Solutions at a concentration of 0.0025 w/v% are very light brown. Thus, for cosmetic reasons, not all solutions may be acceptable. However, because they are neutral to anionic polymers, synthetic humic acid will have a low affinity for plastic materials and therefore the materials will not be discolored if the synthetic humic acid compositions are formulated properly.

Example 22

One-bottle contact lens multipurpose disinfecting, preservation (storage), cleaning, rinsing and re-wetting solution containing an anti-microbial amount of synthetic humic acid from 2,5-dihydroxyphenylacetic acid (homogentisic acid). The aqueous solution has the following composition:

Ingredient	%w/v
Synthetic humic acid	0.0025
Edetate disodium, USP	0.050
Hydroxypropylmethylcellulose	0.20
Boric acid, NF	0.39
Sodium borate decahydrate, NF	0.20
Sodium chloride, USP	0.40
Pluronic F-127	0.10
pH adj. w/NaOH or HCl	7.4

While this invention has been described fully and completely with special emphasis on several examples, it should be understood that within the scope of the appended claims this invention may be practiced otherwise than as specifically described above.

I CLAIM:

1. A process for preparing synthetic phenolic polymeric materials whose physicochemical properties and attributes are reproducible, and which simulate the physicochemical properties and attributes of typical commercially-available natural humic acids and other soil extracts, which comprises the steps of:

a) dissolving one or more starting organic compounds selected from the group consisting of the compounds listed in Table 1 and Table 2 in an aqueous solution comprising distilled water or sodium hydroxide;

b) adjusting the pH of the aqueous solution resulting from step a) to between 8 and 11 if necessary;

c) adding an alkaline periodate salt or alkaline-earth periodate salt to the aqueous solution resulting from step b);

d) maintaining the temperature of the solution resulting from step c) between 35 and 80°C for a period of 30 minutes to 100 hours;

e) adding one or more compounds or salts selected from the group consisting of boric acid, borate salts, alkaline earth salts, transition metal salts, alkaline sulfides, alkaline earth sulfides or transition metal sulfides to the aqueous solution resulting from step d);

f) allowing the aqueous solution resulting from step e) to stand with or without stirring at room temperature between 2 and 48 hours;

g) removing molecules from the solution resulting from step f) below about 500 to about 10,000 daltons;

h) concentrating the solution resulting from step g); and

i) removing the water from the solution resulting from step h) if necessary.

2. The process according to claim 1, wherein the pH of the aqueous solution resulting from step a) is adjusted to between 8 and 11 by adding aqueous ammonium hydroxide, or other aqueous alkaline oxide or hydroxide, or aqueous alkaline-earth oxide or hydroxide, or aqueous transition-metal oxide or hydroxide, or hydrochloric acid or other inorganic acid.

3. The process according to claim 1, wherein alkaline or alkaline-earth sulfides are added to the solution resulting from step b).

4. The process according to claim 1, wherein transition-metal sulfides are added to the solution resulting from step b).

5 5. The process according to claim 1, wherein alkaline or alkaline-earth sulfides are added to the solution resulting from step c).

6. The process according to claim 1, wherein transition-metal sulfides are added to the solution resulting from step c).

10 7. The process according to claim 1, wherein any precipitate formed from the solution resulting from step f) is removed by centrifugation.

8. The process according to claim 1, wherein step g) is accomplished by dialyzing the solution resulting from step f) with a flow-through apparatus consisting of a sandwich-type membrane of molecular-weight cutoff of 500-10,000 daltons until the conductivity of the retentate solution has dropped to 200 microsiemens or less.

15 9. The process according to claim 8, wherein the solution resulting from step g) is concentrated in step h) by utilizing a flow-through dialysis apparatus that produces a retentate solution such that the volume of the dialysis apparatus retentate solution is allowed to drop.

20 10. The process according to claim 1, wherein the solution resulting from step g) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution.

11. The process according to claim 1, wherein the solution resulting from step g) is autoclaved between 100 and 150⁰C for 5 to 60 minutes to produce a sterile solution.

25 12. The process according to claim I, wherein the solution resulting from step h) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution.

30 13. The process according to claim 1, wherein the solution resulting from step h) is autoclaved between 100 and I 50⁰C for 5 to 60 minutes to produce a sterile solution.

14. The process according to claim 1, wherein mannose or other static electricity reduction material is added to the solution resulting from step h) prior to removing the water from said solution in step i).

5 15. The process according to claim 1, wherein step i) is accomplished by S spray-drying or thermally-induced evaporation or vacuum or freeze-drying.

16. The process according to claim 1, wherein the dried powder from step i) is autoclaved between 100 and 150⁰C for 5 to 60 minutes to produce a sterile powder.

10 17. The process according to claim 1, wherein tubular, capillary, coiled spiral, or plane dialysis membranes are used in step g) for removing molecules from the solution resulting from step f);

18. The process according to claim 17, wherein the solution resulting from step g) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution.

15 19. The process according to claim 17, wherein the solution resulting from step g) is autoclaved between 100 and 150⁰C for 5 to 60 minutes to produce a sterile solution.

20 20. The process according to claim 17, wherein the solution resulting from step g) is concentrated in step h) by utilizing a flow-through dialysis apparatus that produces a retentate solution such that the volume of the dialysis apparatus retentate solution is allowed to drop.

25 21. The process according to claim 1, wherein the solution resulting from step g) is further dialyzed with a flow-through apparatus consisting of a sandwich-type membrane of molecular-weight cutoff of 30,000-100,000 daltons to produce an aqueous filtrate solution containing synthetic phenolic polymeric materials of lower molecular weight between 500 and 10,000 daltons and upper molecular weight between 30,000 and 100,000 daltons.

22. The process according to claim 21, wherein tubular, capillary, coiled spiral, or plane dialysis membranes are used for said further dialysis.

23. The process according to claim 22, wherein the solution resulting from step g) is passed through a filter of pore size between 0.2 and 0.4 micron to produce a sterile solution.

5 24. The process according to claim 22, wherein the solution resulting from step g) is autoclaved between 100 and 150°C for 5 to 60 minutes to produce a sterile solution.

10 25. The process according to claim 22, wherein the solution resulting from step g) is concentrated in step h) by utilizing a flow-through dialysis apparatus that produces a retentate solution such that the volume of the dialysis apparatus retentate solution is allowed to drop.

26. A blood product composition comprising an anti-viral amount of a synthetic phenolic polymeric material produced by the process of claim 1 combined with a blood product.

15 27. The composition of claim 26, wherein said blood product is whole human blood.

28. The composition of claim 26, wherein said blood product is human blood platelets.

29. The composition of claim 28, wherein the anti-viral amount is an amount sufficient to reduce human immunodeficiency virus (HIV) activity.

20 30. The composition of claim 28, wherein the anti-viral amount is an amount sufficient to reduce nonenveloped virus activity.

31. The composition of claim 30, wherein the nonenveloped virus is parvovirus.

25 32. The composition of claim 30, wherein the nonenveloped virus is cytomegalovirus.

33. The composition of claim 26, wherein said blood product is human blood serum.

34. The composition of claim 26, wherein said blood product is a human blood protein.

30 35. The composition of claim 34, wherein said human blood protein is human serum albumin or human serum gamma-globulin.

36. The composition of claim 26, wherein said blood product is a human haemophilia factor
37. The composition of claim 36, wherein the human haemophilia factor is factor VIII.
- 5 38. The composition of claim 36, wherein the human haemophilia factor is factor IX.
39. The composition of claim 36, wherein the anti-viral is an amount sufficient to reduce human immunodeficiency virus (HIV) activity.
40. The composition of claim 36, wherein the anti-viral is an amount
10 sufficient to reduce nonenveloped virus activity.
41. The composition of claim 40, wherein the nonenveloped virus is parvovirus
42. The composition of claim 40, wherein the nonenveloped virus is cytomegalovirus
- 15 43. A method of reducing the amount of virus in a blood product by contacting said blood product with an anti-viral amount of a synthetic phenolic polymeric material produced by the process of claim 1.
44. The method of claim 43, wherein said contacting consists of sterily breaking a seal in a connecting path between two separate chambers, one of which
20 contains said blood product in a sterile form and the other of which contains said anti-viral amount of said synthetic phenolic polymeric material in sterile form.
45. The method of claim 43, wherein said contacting consists of injecting a sterile solution containing said anti-viral amount into said blood product.
46. The method of claim 43, wherein said virus is Human Immunodeficiency
25 Virus (HIV).
47. The method of claim 43, wherein said virus is Hepatitis A virus.
48. The method of claim 43, wherein said virus is Hepatitis B virus.
49. The method of claim 43, wherein said virus is Hepatitis C virus.
50. The method of claim 43, wherein said virus is parvovirus.
- 30 51. The method of claim 43, wherein said virus is cytomegalovirus.

52. The method of claim 43, wherein one or more additional blood treatment methods for reducing viral activity are employed.

53. The method of claim 52, wherein the additional blood treatment method is the solvent/detergent (SD) method.

5 54. A composition for treating or preventing human or animal diseases caused by a virus comprising an anti-viral amount of a synthetic phenolic polymeric material produced by the process of claim I and at least one physiologically acceptable carrier or excipient.

10 55. The composition of claim 54, wherein the virus is Human Immunodeficiency Virus (HIV).

56. The composition of claim 54, wherein the virus is Herpes Simplex Virus Type I or Type II.

57. The composition of claim 54, wherein virus is a picornavirus.

15 58. The composition of claim 54, wherein the physiologically acceptable excipient is an injectable solution excipient.

59. The composition of claim 54, wherein the physiologically acceptable excipient is a topical formulation excipient.

60. The composition of claim 54, wherein the physiologically acceptable excipient is an ingestible excipient.

20 61. The composition of claim 54, wherein the physiologically acceptable excipient is a nasal spray excipient.

62. The composition of claim 54, wherein the physiologically acceptable excipient is a metered-dose inhaler excipient.

25 63. The composition of claim 54, wherein the physiologically acceptable excipient is a vaginal or anal suppository excipient.

64. The composition of claim 54, wherein the physiologically acceptable excipient is suitable for disinfection or preservation of a medical device.

30 65. Compositions for treating or preventing human or animal microbial induced diseases comprising an antimicrobial amount of a synthetic phenolic polymeric material produced by the process of claim 1 and at least one physiologically acceptable excipient.

66. The composition of claim 65, wherein the physiologically acceptable excipient is an injectable solution excipient.

67. The composition of claim 65, wherein the physiologically acceptable excipient is a topical formulation excipient.

5 68. The composition of claim 65, wherein the physiologically acceptable excipient is an ingestible excipient.

69. The composition of claim 65, wherein the physiologically acceptable excipient is a nasal spray excipient.

10 70. The composition of claim 65, wherein the physiologically acceptable excipient is a metered-dose inhaler excipient.

71. The composition of claim 65, wherein the physiologically acceptable excipient is a vaginal or anal suppository excipient.

72. The composition of claim 65, wherein the physiologically acceptable excipient is suitable for disinfection or preservation of a medical device.

15 73. The composition of claim 72, wherein the medical device is a contact lens.